Proposal for a Council Directive on the legal protection of biotechnological inventions. COM (88) 496 final, 17 October 1988 by unknown
COMMISSION  OF  THE  EUROPEAN  COMMUNITIES 
COMC88)  496  final  - SYN  159 
Brussels,  17  October  1988 
PROPOSAL  FOR  A COUNCIL  DIRECTIVE 
ON  THE  LEGAL  PROTECTION 
OF  BIOTECHNOLOGICAL  INVENTIONS 
(presented  by  the  Commission> ---1-
EXPLANATORY  MEMORANDUM 
PART  ONE:  GENERAL 
c o  n  t  e  n  t  s 
Introduction 
Purpose  and  Scope  of  the  Proposed  Directive 
Subject  Matter  of Biotechnology 
Main  Areas  of  Inventive  Work  and  Their  Economic  Importance 
Categories of Biotechnological  Inventions 
The  Need  for  Approximation  of  Laws 
(i)  Existing Legal  Framework  in the  Member  States 
(ii)  Efforts to  Improve  Legal  Protection  for  Biotechnological 
Inventions 
(iii)  Protection of  Biotechnological  Inventions~der the  European 
Patent  Convention 
(iv)  Effects of  the  European  Patent  Convention  upon  the  Protection 
of Biotechnological  Inventions  under  National  Patent  Laws 
(v)  Effects of  the  Community  Patent  Draft  Convention  upon  the 
Protection of Biotechnological  Inventions  under  the  European 
Patent  Convention  and  under  National  Patent  Laws 
Cvi)  Protection of Biotechnological  Inventions  by  the  Courts 
<vii)  Necessity  for  the  ComMunity  to Act - 2  -
Relationship between  the  proposed  Directive  and  the  European  Patent  Convention 
Relationship between  the Patent  Protection under  the  Proposed  Directive  and 
the Protection of  Plant  Breeders'  Rights  under  the  UPOV  Convention  and 
National  Plant Variety  Laws 
Legal ·Basis 
Part  II:  Particular Provisions 
Chapter  1:  Patentability of  Living  Matter 
Chapter  2:  Scope  of Protection 
Chapter  3:  Dependency  License  for  Plant  Varieties 
Chapter  4:  Deposit,  Access  and  Re-deposit 
Chapter  5:  Reversal  of  the Burden .of  Proof 
Chapter  6:  Definitions and  Final  Provisi~ns - 3  -
EXPLANATORY  MEMORANDUM 
PART  ONE:  GENERAL 
WTRODUCTION 
1.  In· a  1983  Communication  to the  Council  entitled "Biotechnology  in the 
Community",  the  Commission  emphasised  the  increasing  importance  for  medicine, 
industry and  agriculture of  applications of  modern  biotechnology1•  The 
Commission  noted that  European  lack  of  strength  in this field  results 
principally from  the  fragmentation  of its efforts  in  research  and  from  the 
absence  at  Community  level  of  a  favourable  environment  for  innovation.  To 
remedy  the situation, the  Commission  undertook  several  initiatives covering 
the  problems  posed  by  the  recent  evolution of  modern  biotechnology. 
In  the  field of  research,  the  Commission  included  biotechnology and  the 
various  areas  covered  by  the exploitation and  promotion  of  biological 
resources  among  the eight  priorities of  the  Framework  Programme  for  1987-1991. 
The  present  Action  Programme  "Biotechnology"  (BAP:  7SM  Ecu  for  the  period 
1985-1989)  includes  research activities, training  and  collective action to 
promote  the  creation of neu  processes  for better mastery  and  exploitation by 
man  of  the  properties  and  structures of  living matter.  BAP,  based entirely on 
European  cooperation,  controls  and  directs some  350  research  contracts grouped 
into 90  transnational  projects and  assures  each  year,  for  about  100  young 
researchers,  specialised training  indispensable  for  the  development  of 
biotechnology;  it also  includes  numerous  scientific projects, notably  in the 
fields  of  plant  molecular  genetics, of  industrial  microbiology  and  of protein 
genetics, which  contribute significantly to the  innovatory  potential of 
agriculture and  of  Community  industry.  Several  programmes  will be  initiated 
shortly to permit  an  increase  in ongoing  activities and  to  extend  them  to 
solving  Community  problems  arising at  the  interface between  industry and 
agriculture.  This  concerns,  on  the one  hand,  the  BRIDGE  Proaramme 
(Biotechnology  Research  for  Innovation,  Development  and  Growth  in  Europe,  with 
a  proposed  budget  of  100M  Ecu  covering the  period 1990-1994),  which  is in 
preparation by  the  Commission  services  and  which  will  be  taken  over  in 1990 
------------------------
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with  BAP;  and,  on  the other  hand,  two  new  programmes,  ECLAIR  and  FLAIR, 
presented  by  the  Commission  to  the  Council  in  1987  and  1988,  which  are  aimed 
at  promoting  the  development  in the  Community  of  agro-industrial  and 
agro-alimentary  technologies.  ECLAIR  (European  Collaborative  Linkage  of 
Agriculture  and  Industry  through  Research)  ha~ a  proposed  budget  of  80M  Ecu 
covering  the  period  1989-1993;  FLAIR  (Food-Linked  Agro-Industrial  Research) 
has  a  proposed  budget  for  mid-1989  to mid-1993  of  25M  Ecu.  Commission 
initiatives  in  favour  of  research  and  development  in  the  field  of 
biotechnology  would  remain  incomplete  if they  were  not  accompanied  by 
appropriate  industrial  property  legislation which  offers  to  Community  science 
and  industry  Legal  protection  indispensable  for  their  inventions.  The  legal 
situation  in  the  Community  was  identified  in  the  1983  Communication  to the 
Council  as  suffering  from  deficiencies  and  discrepancies  in  statute  law  and  a 
general  shortage of  case  law.  The  problem  raised  by  the  absence  of  a 
harmonised  system  of  Laws  was  said to be  particularly harmful  and  dangerous  to 
an  entity  like  the  European  Communities  in  view  of  the  impact  on  Community 
industry  and  on  the  functioning  of  the  common  market.  Specific  action at 
Community  Level  was  envisaged  on  the basis. of  the  major  unresolved  legal 
issues  presented under  biotechnology.  It was  therefore advocated  that  the 
Commission  should  work  out  proposals  to the  Council,  inter alia,  for  a 
European  approach  to  intellectual property  rights  in biotechnology. 
2.  Following  a  "guidelines discussion"  at  the  Research  Council  of  the 
European  Communities  of  28  February  1984  on  the  Communication  from  the 
Commission  and  as  to  suggested  Community  action,  the  Council  concluded  that  it 
was  advisable  to take  measures  as  proposed  by  the  Commission  to  improve  the 
regulatory environment,  including  the  system  of  intellectual  property  rights, 
with  a  view  to facilitating  the production,  marketing  and  use  of 
biotechnological  products  in  the  Community.2 
3.  Subsequently,  in its White  Paper on  "Completing  the  Internal  Market" 
approved  by  the  Community  Heads  of State and  Government  at  the  European 
Council  meeting  in Milan  on  28/29  June  1985,  the  Commission  announced  its 
intention to propose  measures  concerning patent protection of  biotechnological 
.  .  3  1nvent1ons. 
------------------------ 2 SI(84)  144,  Annex  IV. 
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4.  The  Single  European  Act,  adopted  by  the  Conference  of  the  Represcnt~tive~ 
of  the  Governments  of  the  Member  States on  28  February  1986  in  The  Hague, 
established' a  new  Article  8A  of  the  EEC  Treaty  providing  for  the  Community  "to 
adopt  measures  with  the  aim  of  progressively establishing the  internal  market 
over  a  period expiring on  31  December  1992". 
5.  At  the  time  of  signing  the  text of  the  Single  European  Act,  the  Conference 
adopted  the  following  declaration on  Article  8A: 
The  Conference  wishes  by  means  of  the provision  in  Article  8A  to express 
its firm political will  to  take  before  1  January  1993  the  decisions 
necessary  to  complete  the  internal market  defined  in those provisions, 
and  more  particularly the decisions  necessary  to  implement  the 
Commission's  programme  described  in the  White  Paper  on  the  Internal 
Market. 
6.  This  proposal  is one  of  the  measures  aimed  at  providing  industry  with  the 
ability to treat  the  common  market  as  a  single environment  for their economic 
activities and  to  create  the  conditions  necessary  for  the  proper  functioning 
of  the  common  market. 
Differences  in  industrial  property  laws  have  a  direct  and  negative  impact  on 
Community  trade  and  there  is no  other  field of  technology  where  national 
patent  laws  vary  on  so  many  points  as  they  do  in biotechnology.  To  create the 
environment  for  companies  to treat the  common  market  as  a  single market,  it 
is essential  to  reduce  to  a  minimum  the existing differences  in  the  legal 
protection of  biotechnological  inventions  and  to prevent  others  from  arising. 
7.  The  proposal  is necessary  to  provide  authoritative guidance  for  most  of 
the  questions  and  problems  presented  in national  patent  law  which  arise  in 
connection  with  biotechnological  inventions  and  which  are  not  directly 
addressed  by  such  laws.  Without  such  a  proposal,  the existing  lack  of 
uniformity of  approach  makes  it impossible  for  companies  to treat  the 
Community  as  a  single market.  Moreover,  without  approximation  of  national 
Legislation,  the  possibility exists for  an  even  greater variation of  national 
approaches  in  Light  of  the  independence  of  national  patent  systems  and  each 
national  judiciary. - 6  -
Ptlrpcse  <lrlci  Scope  of  the  Proposed  ui rect ive 
~-·--· -----
o.  TliP  main  purpose  of  thic;  orcpos0l  fo1·  a  DirPctive  is tc est;;':ll.ish 
harmorlised,  clear  and  improv~d standards  for  protectina biotechnological 
inventions  iil  Jrd~"r  to  fo~ter tho  overall  innovatory  potential  <::nd 
ccnpLtitiveness  of  Ccmmunity  s~ience and  industry  in  this  important  fielrl  of 
~cdcrn technology.  The  provisions  of  the  Directive systematically adaot 
existing patent  Law  principles  to  the field of  biotechnology  with  the  aim  of 
securing  ~he application of  patent  laws  in this  important  arPa  ;::c;  effective 
a:;  possible. 
9.  By  providing  improved  possibilities to  protP.ct  biotechnological 
inventions  and  greater certainty  regarding  the scope  of  protection available, 
the  Directive  should  allow  inventors  and  investors  in  the  Member  St~tes to 
benefit  from  patent  protection  as effective as  that  in the  competi~ive 
markets  of  Japan  and  the  United  States of  America  (USA).  This  will  result  in 
J  greater  willingness  to  invest  labour  and  capital  in  research  and 
development  and  in exploiting  the  results  thereof  in  spit~ cf  the  high  ri~ks 
involved. 
10.  Establishing  a  ~armonised system  of  patent  law  in  tf1is  area  will 
facilitate  the  development  of  Community  industry  in biotechnology,  trade  ir1 
biotechnological  products  and  the  establishment  of  a  common  market  in this 
field.  ~1oreover,  it will  enable  Community  industry to  keep  pace  with  Leading 
nations  in biotechnology  and  to  close  or  narrow  existing  gaps. 
11.  The  primary  purpose  of  the modern  patent  system  is  to promote  technical 
innovation  as  the  major  factor  of  economic  growth  by  encouraging  inventive 
~ctivity through  rewarding  inventors  for  their creative efforts.  The  patent 
system  thus  secures  costly  investment  in  research  and  development  and 
industrial  exploitation of  research  results.  Simultaneously,  the  patent 
syst0m  encourages  an  early  and  beneficial  dissemination of  knowledge  in  the 
field  of  activity  involved  which,  without  such  protection,  miyht  be  kept 
secret.  The  patent  system  also offers  the  necessary  incentives  for  exploiting 
the  results  of  publicly funded  research.  Such  cxrloitation itself  requires 
costly  investment. - 7  -
12.  Biotechnological  research  and  development  and  industry  making  use  of 
developments  in this  field  are  rapidly evolving  and  expanding  on  the 
international  Level.  Biotechnology  is  Likely  to  influence  and  modify  the 
Lives  of  many  people  through  its ultimate  impact  on  human  and  animal  health 
care,  agriculture,  the  food  and  chemical  industries,  energy  resources  and  the 
environment.  It  has  evolved  dramatically  through  the  advance  of  various 
genetic  engineering  techniques  in  recent  years,  particularly so  in the  USA 
and  Japan.  It is, therefore,  of  particular  urgency  for  patent  protection to 
play  its important  part  in  these  fields  in  the  European  Communities. 
13.  The  patent  system,  when  applied  to biotechnology,  encounters  a  number  of 
particular problems.  A reason  for  this  is that  biotechnology,  as  the  name 
says,  is  related  to  Living  matter,  which  poses  problems  in  relation to ethics 
as  well  as  in  relation  to  the  traditional  patent  Law  concepts  of  patentable 
subject  matter,  discovery,  novelty,  sufficient written disclosure,  industrial 
applicability and  the extent  and  exhaustion  of  patent  protection. 
14.  These  particular problems  have  been  handled  in  some  respects  in  a 
different  manner  in different  Member  States  and,  even  where  Member  States 
have  unilaterally  introduced  into their  Laws  provisions  similar to those of 
the  European  Patent  Convention,  these  provisions  do  not  provide  for  specific 
rules  which  relate  to  and  are  necessary  for  resolving  the  particular problems 
of  biotechnological  inventions.  In  fact,  the  Legal  situation suffers  from 
deficiencies  as  well  as  discrepancies  in statutory  law,  regulations  and their 
interpretation and  a  general  shortage  of  case  Law. 
15.  The  problem  is particularly acute  in  the  European  Communities,  where  the 
existence of  a  harmonised  and  adequate  body  of  Law,  rules  and  practices  is of 
major  importance  to the  proper  functioning  of  the  internal  market  and  the 
competitive  vigour  of  industry. 
Subject  Matter  of  Biotechnology 
16.  Biotechnology  is  understood  to  comprise  all  the  techniques  that  use  or 
cause organic  changes  in  any  biological material  (such  as  animal  and  plant 
cells or  cell  Lines,  enzymes,  plasmids  and  viruses),  microorganisms,  plar1ts 
and  animals;  or  tl1at  cause  changes  in  inorganic  material  by  biological  me~ns. - 8  -
In  its modern  appearance,  biotechnology  includes  the  techniques  of 
recombinant  DNA  <deoxyribonucleic  acid),  gene  transfer,  embryo  mar1ipulation 
~nd transfer,  plAnt  regeneration,  cell  culture,  monoclonal  antibodies,  and 
bioprocess  engineering.  This  understanding  of  biotechnology  covers  the  areas 
in  which  inventive  work  is most  active  and  promising,  and  in  which  the 
results  of  that  work  have  particular economic  and  social  importance. 
Main  Areas  of  Inventive  Work  and  Their  Economic  Importance 
17.  Biotechnology  is  rapidly gaining ground.  It  is playing  an  increasingly 
important  role  in  the  future  of  industry.  Inventive  work  concerns  many 
sectors,  such  as  pharmaceuticals  <e.g.,  the  production of  human  insulin, 
human  hormones,  interferons,  blood  products,  vaccines  and  antibiotics, 
monoclonal  antibodies, genetically engineered  heart  attack drugs,  etc.); 
specialty  chemicals  and  food  additives  (e.g.,  amino  acids,  enzymes,  single 
cell proteins);  commodity  chemicals  and  energy  production  (e.g., biomass 
resources);  and  environmental  applications  (e.g., pollution control,  toxic 
waste  treatment,  microbial  enhanced oil  recovery).  Agriculture  is another 
area  of  biotechnological  activities holding  the  key  to  innovation  crucial  for-
creating  new  products  and  for  ~nhancing environmental  acceptability  in crop 
production  (e.g.,  improvement  of  specific  plant  characteristics,  Like  insect, 
disease,  pesticide,  stress or herbicide  resistence,  use  of  microorganisms  for 
crop  improvements,  etc.),  and  animal  agriculture  <e.g.,  diagnosis,  prevention 
and  control  of  animal  diseases,  animal  nutrition  and  growth  promotion, 
genetic  improvement  of  animal  breeds),  as  well  as  new  bioprocessing 
opportunities  (e.g.,  alternative fuels,  alternative  feed  and  food  sources, 
and  other products). 
18.  Patent  documentation  gives  evidence  of  an  overall  increasing patent 
activity  in biotechnology.  The  most  impressive  increase  took  place  in  the 
field of  "mutation/genetic  engineering",  i.e., in  the  core-region  of  the  new 
biotechnological  developments.  Genetic  engineering  is  composed  of  newly 
emerging  methods  for  inserting,  changing  or deleting genetic  information 
within  a  host  Or<Janism,  be  it microorgc: ...  o.,,,,  plant  or  animal,  to give  it new 
characteristics.  ThP  development  and  usc  cf  these  new  tcchniqups  provide  the 
<:bility  to  rr:anipu~"'1f'  i:he  genetic  char<Jctcr  of  organisms  •.1hile  overcoming 
complications  and  Limitations of  natural  gene  exchange.  lhe  patent  file  of - 9  -
the  European  Patent  Office  reveals  that,  in  the  field  of  genetic  engineering, 
the  number  of  patent  applications  filed  rose  approximately  600%  fro1~  1981  to· 
1985.  About  50%  of  the  applications originated  from  the  USA;  Japan 
contributed more  than  20%;  some  25%  of applications  came  from  the  Member 
States  (United  Kingdom  12.1;  Germany  5.2;  France  5.0;  the  Netherlands  2.3; 
Denmark  0.5;  Belgium  0.2)4 
19.  The  modern  genetic  engineering  techniques  complement,  rather  than 
replace,  the  methods  of  traditional biotechnology,  which  will  continue  to 
yield  new  invention~ as  well.  However,  the  new  techniques  do,  due  to  their 
speed,  precision,  reliability and  scope,  offer  enormous  economic  potential. 
Market  forecasts  for  modern  biotechnological  products  vary  considerably. 
However,  in  no  estimate are  these markets  valued at  Less  than  US  $  40  billion 
by  the year  20005.  It  is believed that  modern  biotechnology  has  its strongest 
research  base  in·the  USA;  and  its strongest  commercial  base  in  Japan6,  with 
Europe  remaining  below  its  real potential.  Member  States,  with  annual 
government  funding  of  biotechnology of  approximately  US  $  350  million7 
should,  therefore,  strive such  as  the  Commission  has  already  begun  <see 
paragraph  1  above)  to  improve  future  prospects  for  Community  industry,  in 
order  to  secure  an  appropriate  stake  in  the  world  markets  for  such  industry. 
P~tent protection,  adapted  to  the  needs  of  modern  biotechnology,  is one 
important  measure  serving  this goal. 
Categories  of  Biotechnological  Inventions 
20.  Inventions  resulting  from  modern  biotechnological  techniques  can  be 
grouped  according  to  the  usual  patent  law  distinction made  between  product, 
process,  and  use  or  application  inventions. 
Inventions  relating to products  concern  living entities of natural  or 
artificial origin,  such  as  plants,  animals  and  microorganisms,  biological 
m~terial,  ~uch  a~  pl2~mids, viruses  and  replicons,  and  parts  thereof  Ce.g., 
~-----------------------
Knuth  et  ;1l ., Char.lctcrization of  Genetic  Engineering  Inventions  in 
Patent  Cl~i~s,  1987  World  Patent  Information  229,  at  230. 
5  Hacking,  Economic  Aspects  of  Biotechnology,  Cambridge  etc.,  1986,  256,  257. 
6  Hacking,  op cit., 254. 
7  Dibner,  232  Science  1367  (1986)  at  1369. - 10  -
organs,  tissues,  cells and  organelles).  They  may  also  relate  to naturally 
occurring  substances  from  living entities, biological  material  and  parts 
thereof.  The  invention  itself may  be  the plant,  animal,  microorganism  or  a 
specific biological  material  (e.g.,  a  plasmid)  per  se  or  the plant,  animal, 
etc., produced  by  a  particular process. 
The  second  category  (process  inventions)  concerns  processes  for  the  creation 
of  plants,  animals,  microorganisms  or  any  biological  material  and  parts 
thereof •.  It  includes  also  such  processes  as  cultivation,  isolation,  and 
purification,  and  also of  bioconversion. 
The  third category  of  biotechnological  inventions  (application  inventions) 
comprises  specific  uses  of  plants,  animals,  microorganisms  or  biological 
material. 
The  Need  for  Approximation  of  Laws 
Ci)  Existing legal  Framework  in  the  Member  States 
21.  The  existing  legal  framework  for  protecting biotechnological  innovation 
in  the  Member  States  has  been  strongly  influenced by  two  international 
conventions,  conceived  in  the  late fifties  and  early sixties  on  the basis  of 
the-then state of  the art  in biological  sciences:  The  "International 
Convention  for  the  Protection of  New  Varieties  of  Plants",  established  in 
1961  in Paris  <the  UPOV  Convention),  and  the  "Convention  on  the  Unification 
of  Certain Points  of  Substantive  Law  on  Patents  for  Invention",  signed  in 
1963  (the  Strasbourg  Convention). 
22.  The  current  patent  laws  of  most  of  the  Member  States  were  adopted  and 
introduced  in  the  late seventies and  early eighties as  a  direct  result  of  the 
more  recent  1973  "Convention  on  the  Grant  of  European  Patents''  (the  European 
Patent  Convention  - EPC)  and  the  "Convention  for  the  European  Patent  for  the 
Common  Market"  <Community  Patent  Convention  - CPC),  signed  in  Luxembourg  in 
1Y75,  but  not  yet  in  force.  With  regard  to biotechnological  innovation,  they 
follow  the basic  principles  of  the  UPOV  and  Strasbourg  Conventions,  which 
were  introduced  into the  EPC  without  seriously  reconsidering  developments 
which  in the Qeantime  had  taken  place  in various  areas  of  biotechnology. - 11  -
23.  The  key  assumptions  of  the  UPOV  and  the  Strasbourg  Conventions,  which 
were  taken  over  into the  EPC  and  the  harmonised  national  natent  laws  of  <ill 
8  the  Member  states,  except  Ireland  and  Portugal  ,  are,  firstly,  the  belief 
that  the traditional  concept  of  "technical  invention••  renders  biological 
inventions  only  in  rare  cases  capable of  complying  with  the  usual 
requirements  of  patentability; and,  secondly,  that  inventions  in the  field of 
living matter  could  be  divided into those  of  microbiology  and  those  of 
(macro-)  biology. 
Based  on  these  premises  and  taking  into account  certain  known  needs  of 
traditional plant  breeders,  the  1961  UPOV  Convention  established a 
tailor-made  type  of  protection for  new  varieties of  plants. 
Subsequently,  the  Strasbourg  Convention,  in view  of  the  long  history of 
patenting microbiological  processes  and  their products  in  several  States 
party  to it, made  it mandatory  as  early as  1963  to protect microbiological 
processes  and  their  resulting products,  but  Left  the  signatory  States  a  free 
hand  as  regards  the  protection of  new  plant  or  animal  varieties and 
essentially biological  processes  employed  in  their production. 
The  EPC,  when  adopted  in  1973, expressly excluded  from  patent  protection 
plant  and  animal  varieties  and  essentially biological  processes  for  the 
production of  plants  and  animals  but  allowed  patenting of  microbiological 
processe~ and  their  products  (Article  53b). 
24.  It  should also  be  mentioned  that  in  1977,  under  the  auspices  of  WIPO, 
the  Budapest 
1'Tre~ty on  the  International  Recognition  of  the  Deposit  of 
r~icroorganisru'S  for  the  Purposes  of  Patent  Procedure
11  was  concluded  to  which 
twenty-one  States  h.:we  9  adhered  •  The  States  party  to this  Treaty,  which 
or  require  the deposit  of  microorg<lnisms  for  the purposes  of  patent 
procedure,  are obliged to  recognise,  for  such  purposes,  the  deposit  of  a 
~icroorganism uith  any  recognised  international depository authority. 
() l l OH 
------------------------ 8  These  Member  Statrs  have  not  yet  brought  their national  patent  law~  into 
line  ~.-~ith  EPC. 
9  As  of  April  1?87.  From  the  Co~munity Member  States  Greece,  I~ela~d, 
Luxembourg,  ~nd Portugal  are not  yet  party to this  Treaty. - 12  -
Although  this  Treaty  facilitates  applications  for  patent  protection of 
biotechnological  inventions  abroad,  it does  not  influence  the  substantive 
patent  Law  of  the  "Contracting States".  Its  influence  on  patent  Laws  of  the 
Contracting  States  is  limited to purely  technical  provisions  regarding  the 
depositing  and  redepositing of  microorganisms,  as  demonstrated  by  Rule  28a 
EPC,  which  was  inserted  into the  EPC  Regulations  as  a  result  of  the 
conclusion of  the  Budapest  Treaty. 
25.  Achievements  in biotechnology  reached  during  the  period  of  time 
necessary  to bring  into  fore~ this  international  legal  framework  at  the 
national  level  demonstrate  that  the distinction between  micro- and 
macrobiology,  ~hich serves  as  the  dividing  line between  patentable  and 
non-patentable  inventions,  is artificial  and  no  longer  tenable.  Developments 
originating  in microbiology,  either as  processes  or products,  are  Likely  to 
have  a  direct  effect  on  the  macrobiological  sector,  giving  rise similarly to 
visible  changes  in  the  plant  or  animal  world.  They  should,  therefore,  enjoy 
Legal  treatment  according  to  the  same  principles  as  other  inventions  in 
microbiology. 
26.  One  major  consequence  of  micro- and  biotechnological  developments  is 
that  "Agriculture  has  moved  from  a  resource-based  to  a  science-based  industry 
as  science  and  technology  have  been  substituted for  land  and  labor"10•  A. 
greatly  improved  understanding  and  mastery  of  basic biological  mechanisms 
have  given  rise to  a  change  in  the  concept  of  what  may  be  considered 
"technical"  for  purposes  of  patent  Law.  Beginning  in  the  late sixties,  the 
courts  of  at  least  one  Member  State  have  held  that  the general  field  of 
biology  may  be  included  in  the  notion of  what  is "technical".11  This  changed 
appreciation  from  that  represented  by  the existing  international  legal 
framework,  however,  has  only partially been  incorporated  into  statutuory  law 
and  into patent  practice, at  both  the  national  and  the  international  level. 
------------------------ 10  Committee  on  a  National  Strategy for  Biotechnology  in  Agriculture 
-Board on  Agriculture- National  Research  Council,  Agricultural 
Biotechnology  - Strategies  for  National  Competitiveness,  Washington, 
D.C.,  1987,  1,  2.  According  to  the  Execu~ive Summary  of  t~i:  ··:port, 
it  is  true  even  for  USA  that  ''Yet  current  political  and  econn~ic policies 
governing  agriculture neither fully  recognize  nor  take  these  changes  into 
account". 
11  Decision of  March  27  1969,  Federal  Supreme  Court,  Federal  Republic  of 
Germany,  1  IIC  136  (1970>  "Red  Dove". - 13  -
27.  Due  to its underlying  assumptions,  outdated  by  scientific  and 
technological  developments,  the  present  legal  framework  for  protecting 
biotechnological  inventions  in the  Member  States  is  unable  to  satisfy either 
the  needs  of  science  and  industry  in this  field  or  the  needs  of  patent 
granting authorities  and  courts.  Apart  from  the  now  rather questionable 
explicit  exclusions  from  patentability,  only  in  part  resulting  from  the 
prohibition of  double  protection established  in  Art.  2  (1)  UPOV  Convention, 
the  main  and  decisive deficiency of  the  system  is to  be  seen  in  its almost 
complete  tack  of  any  reliable  legislative guidance  on  such  essential 
questions  as: 
Patentability of  Living  Matter,  that  is,  what  are  the  criteria to patent 
natural  material  in  view  of  the existing exclusion of  discoveries  from  patent 
protection and  also  in  view  of  the  novelty  requirement;  what  is  to  be 
understood  by  the  terms  "microbiological"  and  "essentially biological 
process";  can  a  microorganism  per  se  be  regarded  as  a  product  of  a 
"microbiological  process"; 
What  are  the effects of  the  exclusion  from  patentability of  plant  and  animal 
varieties upon  the  patenting  of  microorganisms  or  taxonomic  units different 
from  plant  or  animal  varieties or  upon  the  patenting  of parts  of  plant  ot· 
animal  varieties or their uses?; 
What  is the  Scope  of  Patent  Protection  for  Living  Matter,  in  view  of  the  fact 
that  living matter  is self-replicable and,  this  therefore,  causes  particular 
problems  in  respect  of  further generations; 
Sufficient  Disclosure,  which  in  spite of  the  advances  in natural  sciences 
remains  a  problem  of  major  concern,  for  example,  whether  and  under  what 
conditions  the  written description of  an  invention  may  be  completed  by  a 
deposit  of  a  microorganism or other self-replicable matter,  and  what  are  the 
duties of  and  safeguards  for  the depositor. 
(ii)  Efforts  to  Improve  Legal  Protection  for_~~C:!_~<:__!:~ological  Inventions 
28.  OECD.  Since  the  emergence  of  modern  biotechnology,  the  ability of  patent 
laws  to offer effective protection  for  new  biotechnological  processes  and 
products  has  been  uncertain.  The  Organization for  Economic  Cooperation  and - 14  -
Development  (OECO)  first  initiated an  international  review  on  biotechnology 
and  patent  protection  in 1981.  Based  on  replies  to a  questionnaire  from 
12  .  13  governments  of  nineteen  members  (out  of  twenty-four),  the  F1nal  Report 
detected  a  great  number  of  deficiencies  in  patent  laws  of  most  of  the  member 
countries  regarding  especially the patentability of  microorganisms  per  se, 
naturally occurring materials; disclosure,  deposit  and  release  conditions  and 
infringement.  Moreover,  it was  observed  in this  report  inter alia: 
"In no  other field  of  technology,  old or  new,  do  national  Laws  vary  on 
so  many  points or  diverge  so  widely  as  they  do  in biotechnology.  The 
answers  to the  OECD  Questionnaire  have  brought  a  wide  spectrum of 
varying  legal opinions  and practices  to  Light  which  concern  almost 
every  important  aspect  of patent  protection  in  biotechnology.'' 
The  replies  from  the  Member  States of  the  Community  reflected no  less a 
divergence either in  respect  of  varying  legal  opinions  and  practices or  as  to 
existing deficiencies of national  laws.  It was  felt  that  only  US  and  Japanese 
laws  were  on  the  whole  adaptive  and  flexible  in  respect  of  new  developments  in 
biotechnology.  To  improve  the present  legal  situation  in  the  OECD  countries, 
the  ~eport submitted  a  number  of  recommendations. 
29.  WIPO.  At  its fourteenth  series of  meetings  (of  September/October  1983), 
the  Assembly  of  the  International  <Paris)  Union  for  the  Protection of 
Industrial  Property  instructed  the  International  Bureau  of  the  World 
Intellectual Property  Organization  <WIPO)  to 
"study the existing situation concerning  the protection,  by  patents  or 
by  other means,  of  inventions  in  the  field  of  biotechnology  (including 
'genetic engineering')  and  possible  means  of  providing  for  industrial 
property protection for  such  inventions,  both  at  the  national  and 
international  level"14• 
------------------------
12  Among  those  countries  which  answered  the  Questionnaire  were  the 
13 
following  Member  States:  Belgium,  Denmark,  Germany,  France,  lreland, 
Italy,  the  Netherlands,  Portugal  and  the  United  Kingdom. 
Biotechnology  and  Patent  Protection - an  International  Review,  OECD, 
Paris  1985. 
14  WIPO  Doc.  BIOT/CE/I/2. - 15  -
A Comrnittee  of  Experts  on  Biotechnological  Inventions  and  Industrial  Property 
was  established and  first  convened  in  1984.  Subsequently  the  International 
Bureau  of  WIPO  prepared  an  Analysis  of  Certain Basic  Issues  in  Industrial 
Property Protection of  Biotechnological  Inventions15  and  then,  based  on 
l .  .  .  16  b  .  d  .  .  f  l  .  rep  1es  to  two  auest1onna1res  ,  su  m1tte  n1neteen  suggest1ons  or  so  ut1ons 
concerning  industrial property protection of  biotechnological  inventions17 
These  solutions  seem  to  complete  and  supplement  the  recommendations  of  the 
OECD  Report. 
In  three  meetings,  the  Committee  of  Experts  discussed  the  work  done  by  the 
International  Bureau  and  its consultants,  particularly the  "Suggested 
Solutions"18•  It might  initially have  been  envisaged  that  the  ongoing  work  of 
WIPO  could  have  produced the necessary  level  of  harmonisation  for  the  European 
context.  This  will  unlikely  be  the  case  in  anything  but  the  very  long  term  in 
light  of  the  general  observation of  the  Director  General  of  WIPO  in  the  third 
session of  the  Committee  of  Experts,  according  to  which 
"At  present,  WIPO  did  not  intend  to  provoke  changes  in  national 
legislations;  it only  wanted  to  make  governments  more  aware  of  what  was 
happening  in this  field  in  the various  countries  and  of  what  were  the 
problems  that  the  legislator  ~ight have  to solve,  so  th~t the  patent 
system  could  be  fully  responsive  to  the  need  for  protection  in  this 
exceedingly  important  technological  field." 
Moreover,  from  the  remarks  made  by  a  number  of delegations,  especially,  but 
not  exclusively  from  the  developing  countries,  it may  be  concluded  that  an 
agreement  on  this topic  at  the universal  level either in the  form  of  a  special 
convention or within  the  current  work  of  the  International  Bureau  of  WIPO  on 
the  Draft  Treaty  on  the  Harmonisation of  certain provisions  in  laws  for  the 
protection of  inventions19  cannot  be  expected  for  at  least  several  more  years. 
15----------------------
WIPO  Doc.  BIG  281  and  WIPO  Doc.  BIOT/CE/II/2. 
16  WIPO  Doc.  BIOT/Q/1,  2. 
17  WIPO  Doc.  BIOT/CE/III/2. 
18  The  work  of  the  Committee  is  reported  in  WIPO  Docs.  BIOT/CE/I/3; 
BIOT/CE/II/3;  BIOT/CE/III/3. 
19  WIPO  Doc.  HL/CE/III/2. - 16  -
30.  Thus,  the efforts of  WIPO  in  this area  will  most  likely end  in  no  more 
than  a  recommendation  addressed  to the  Member  States  of  WIPO  by  its Director 
General.  In  view  of  the  complexity  of  the  issues  and  the  interests  involved, 
it is only  realistic  to note  that  such  a  recommendation  could  result  in 
changes  in national  legislation, at best,  in  several  years.  Notwithstanding 
well  founded  and  balanced  Suggested Solutions,  the  WIPO  initiative is  unlikely 
to  bring  about  a  prompt,  positive  and  harmonised  response  at  the  world  or  even 
the  European  level.  Experience  with  the  revision  work  on  the  Paris  "Convention 
for  the  Protection of  Industrial Property"  confirms  this appreciation. 
(iii)  Protection of  Biote~hnological Inventions  under  the  European  Patent 
Convention 
31.  The  legal basis  for  granting  European  patents for  biotechnological 
inventions  is the previously  mentioned  Article  53  (b)  EPC,  which  has  served  as 
a  model  for  national  patent  Law  provisions  of  nine  Member  States of  the 
Community.  As  noted earlier, this article expressly excludes  from  patent 
protection plant  and  animal  varieties and  essentially biological  processes  for 
producing  plants  and  animals  but  allows  patenting of microbiological  processes 
and  the  products  thereof.  Article  53  (b),  however,  is  not  the only provision 
of  the  EPC  explicitly dealing  with  biotechnological  inventions.  Because 
inventions  concerning microbiological  processes  and  their  products  incur 
particular difficulties with  regard  to the  usual  requirement  of  sufficient 
disclosure,  the  EPC  from  the outset  introduced  special  provisions  for 
compliance  with  this patent  law  requirement. 
In  Rule  28  of  the  Regulations,  if an  invention  concerns  a  microbiological 
process  or  the  product  thereof  and  involves  the  use  of  a  microorganism  which 
is not  available  to  the  public  and  which  cannot  be  described  in  such  a  manner 
as  to enable  the  invention to be  carried out  by  a  person  skilled  in the art, 
the disclosure  requirement  may  be  satisfied by  a  deposit  of  a  culture of  the 
microorganism  in  a  culture collection not  later than  the  European  patent 
application date,  including  with  the application  identifying details of  the 
deposit.  The  deposited microorganism must  be  made  available  from  the  culture 
collection  to  any  person  from  the date  of  first  publication of  the 
application.  Moreover,  this provision  lays  down  detailed  rules  as  to  the 
release  conditions of  the  deposited material.  Rule  28  was  subsequently  amended - 17  -
to  introduce  the  so-called  ''expert  solution"  which  allows  the  applicant  the 
possibility to  Limit  the  availability of  the deposited  material  to  an 
independent  expert  until  the  grant  of  the  European  patent. 
32.  To  cope  with  problems  emerging  from  patent  applications  in  the  field of 
modern  biotechnology,  additional  guiding measures  proved  necessary  under 
Article  53  Cb)  EPC.  The  European  Patent  Office  CEPO)  in its "Guidelines  for 
Examination"  therefore  addressed  a  numb~r: of  particular  problems,  such  as,  the 
patentability of  naturally occurring  substances,  the  demarcation  between 
"essentially biological"  and  "essentially non-biological"  processes  and  the 
interpretation of  the  terms  "microbiological  process",  "microorganism",  and 
"product  of  a  microbiological  process". 
As  to other  questions,  such  as  the effects of  the  exclusion  from  patentability 
of  plant  and  animal  varieties  upon  the  patenting of  taxonomic  units different 
from  plant  or  animal  varieties or  upon  the  patenting of  parts  of  plant  or 
animal  varieties  or  their uses,  the  guidelines are  silent. 
33.  Although  the  solutions  provided  for  in  the  Examination  Guidelines  of  the 
EPO  offer  valuable  guidance  for  the  examining  org~ns of  the  EPO,  and  seem  to 
meet  many  of  the  needs  of  applicants  in an  appropriate  manner,  they  are 
handicapped  by  the  fact  that  they are neither  binding  on  the  Board  of  Appeals 
of  the  EPO,  deciding  in  final  instance  on  patentability,  nor  on  national 
courts  competent  in nullity procedures  regarding  European  patents.  There  is no 
mechanism  in  t~e  EPC~  such  as  by  Examination  Guidelines,  to provide  for 
m3nJatory  guidance  on  the  questions  arising  in  respect  of  patenting 
biotechnological  inventions.  The  Goards  of  Appeals  of  the  EPO  and  the  national 
courts  Enjoy  complete  discretion  whether  to  follow  the  practice of  the  EPO 
~11len  interpreting the  EPC.  A;.,  regard::;  the  scope  of  protection of 
biotechnoloqical  invention~  and  the  interrelation between  the effects of 
ratents  and  plant  brP.eders'  rights,  the  EPC  does  not  regulate  these  issues  and 
thus  no  competen~e of  the  European  Patent  Office exists. 
34.  Diffi~ult to predict  are  future  developments  as  regards  the  EPC.  For  the 
tin<C'  being  the  EPO  is  solving  J,Jroblerns  related  to  the  application of  Article 
53  (b)  EPC  on  a  cas~-by-case  basi~  in  addition to periodic  amendment  of the 
Guidelines  fo:- f::x.:Jminati011.  The  p:·ar,ticill  effects of  these  Guidelines  slwuld 
not  be  •muerestim<:.ted.  U'  ','iC~I  of  their  Limited  le('al effects,  hca,t:vcr,  the - 18  -
EPO  Guidelines  cannot  be  viewed  as  a  suitable means  to  cure  the deficiencies 
caused  by  the  lack  of  legislative guidance  with  regard  to  the  most  essential 
problems  of  patenting biotechnological  inventions  under  Article  53  (b)  EPC. 
While  in  theory  it may  be  possible  to  introduce  rules  related to the 
interpretation of  substantive patent  law  provisions of  the  EPC  into the 
"Implementing  Regulations  to  the  Convention"  (the  amendment  of  which  falls 
within  the  competence  of  the  Administrative  Council  of  the  European  Patent 
Organization),  these  Regulations  so  far  have  no  binding  effect  on  the  views  to 
be  taken  by  the  courts  of  the  Contracting  States  when  interpreting  the  EPC. 
The  same  is true  even  for  the  Boards  of  Appeals  of  the  EPO:  under  Article  164 
(2)  EPC,  the  Implementing  Regulations  may  be  deemed  to be  in  conflict  with  the 
wording  of  the  Convention  and.  the  Convention  may  be  interpreted  in  a  different 
way. 
Legislative  guidance  needed  under  Article  53  (b)  EPC  could  of  course  be 
provided  by  a  revision of  the  EPC.  In  light  of  the difficulties presented  by 
the  revision  mechanism  of  Article  172  EPC,  howeve~, it appears  unlikely that 
the  EPC  Contracting  States  would  consider  any  revision  at  the present  time. 
Civ)  Effects  of  the  European  Patent  Convention  upon  the  Protection  __  of~ 
Biotechnological  Inventions  under  National  Patent  Laws 
35.  When  considering  the possibilities of  the  EPC  to affect  the  national 
patent  laws  of  the  Community  Member  States,  the  special  legal  concept  of  the 
EPC  must  be  taken  into  account.  Although  the  EPC  provides  for  a  system  of  law 
for  granting  European  patents,  these  patents,  in  each  of  the  Contracting 
States  for  which  they  are granted,  have  the  effect  of  and  are  subject  to  the 
same  conditions  as  a  national  patent granted  by  that  State  (Articles  1  and  2 
EPC).  A European  patent  is granted,  defined  and  revoked  in  applying  rules  of 
the  EPC,  and  to this extent  represents  a  collection of  "European"  patents.  For 
all other purposes,  such  as  the  scope  of  protection,  European  patents 
represent  patents  with  national  effects,  subject  to national  laws,  although 
certain minimum  standards  are orescribed  in  Articles 64(2)  and  67  EPC. 
In  addition,  it  results  from  the  design of  the  EPC  that  the  Contracting  States 
are  not  obliged automatically  to align their national  patent  laws  with  the 
EPC.  This  has  happened  in  the past  but  on  a  purely voluntary,  unilateral, - 19  -
uncoordinated  basis.  An  amendment  of  the  EPC  would  probably,  but  not 
mandatorily,  lead  to  changes  in national  patent  laws  of  most  of  the  ComMunity 
Member  States.  ~1oroever,  in order  to  secure  a  harmonised  judicial practice on 
points essential  to biotechnological  inventions  in  the  Contracting States, 
such  changes  of  the  EPC  would  require  highly  specific provisions.  An 
additional difficulty with  regard  to  the  EPC  results  from  its membership: 
whereas  four  EPC  Contracting States  are  not  Community  Member  States,  Denmark, 
Ireland  and  Portugal  are  not  yet  Contracting Parties  to the  EPC. 
(v)  Effects of  the  Community  Patent  Draft  Convention  upon  the  Protection  of 
Biotechnological  Inventions  under  the  European  Patent  Convention  and 
under  National  Patent  Laws 
The  ''Convention  for  the  European  Patent  for  the  Common  Market"  of  1975 
(''CPC")  and  the  1985  Agreement  relating to  Community  Patents20  do  not 
themselves  address  questions  ~s to patentability,  but  leave  these  issues to 
the  EPC.  The  CPC  will  not,  therefore,  improve  the ability to  protect 
biotechnological  invention3.  It  is  only  to  the  extent  that  the  EPC  provides 
for  patent  protection  that  the  CPC  will  provide  for  instruments  necessary  to 
secure  that  Community  patents  shall  have  a  unitary  character  as  well  as: 
"have  equal  effects  throughout  the  territories  to  which  this  Convention 
applies  and  may  only  be  granted,  transferred,  revoked  or  allowed  to 
Lapse  in  respect  of  the  whole  of  such  territories  ••.  "  (Article  2  (2) 
CPC). 
Thus,  the  CPC  will  not  provide  a  solution  to  the  basic  issue of  appropriately 
protecting biotechnological  inventions.  Even  for  the positive effects which 
the  CPC  rr'a>'  h;we  on  the  unitary nature  of  protection,  it is difficult  to 
predict  its entry  into force.  This  is unlikely to occur  before  1993  and  may 
Yell  come  into force  for  less than all  Member  States of  the  Community.  The 
possibility also eYists that  the  CPC  will  leave  open  a  permanent  option 
between  ~  Co~m~nity pntent  and  a  European  Patent.  Alongside  the  EPC/CPC 
structure,  national  patent  laws  will  continue  to exist.  Thus,  even  the  entry 
2oC-f--. --:T--·----·- ··---b--l~-h-- .  '  I  L  b  C  f  ~  ...  . 
ext:.;  est<"\,  1::0  e,~  c~·  t  ,,.  uxcn  ourg  on  ererce  on  tne  .. onmun1 ::y  P<~tern. 
1985"  (Council  v:  the  Lurop-:.:c;H  r.x.lmi.lni ties,  Luxembourg  19~16>. - 20  -
into  force  of  the  CPC  would  by  no  means  mave  superfluous  amendments  of 
national  laws  providing  for  legislative guidance  as  to  the  protection of 
biotechnological  inventions  under  national  patent  law. 
<vi)  Protection of  Biotechnological  Inventions  by  the  Courts 
36.  From  past  experience  with  the  judicial  practice of  the  courts  of  the 
Member  States,  it  may  be  observed  that  courts  would  prefer,  perhaps  even  need 
to  have,  more  Legislative guidance  when  dealing  with  problems  of  patentability 
in  the  field of  biotechnology.  As  an  example  of  the difficulties encountered 
by  the  courts  in  the  Member  States  and  of  the  time  needed  to  find  solutions 
for  questions not  specifically answered  in  the  Law,  the  case  Law  of  the  German 
Federal  Supreme  Court  on  the  repeatability  requirement  of  biotechnological 
inventions  may  be  mentioned. 
This  Court  first  demonstrated  its exceptional  understanding  of  the  necessity 
to  interpret  in modern  patent  Law  the  concept  of  invention  according  to  the 
Latest  state of  scientific  knowledge  in  1969  and  affirmed  that  a  method  for 
breeding  animals  is eligible for  patent  protection,  provided  the  procedure  is 
repeatable,  i.e.  it  can  be  readily duplicated  by  a  person  skilled  in the 
21  art  . 
Six  years  later,  when  the  patentability of  a  microbiological  process  and  of  a 
microorganism  per  se  i.e., a  product  claim,  was  at  issue,  the  German  Federal 
Supreme  Court  affirmed its position as  regards  the  patentability of  living 
matter  in general.  It  also  accepted  the deposit  of  a  microorganism  strain 1n 
a  publicly accessible depository as  a  valid  support  of  the  written description 
as  far  as  the microbiological  process  was  concerned,  but  not  in  respect  of 
claims directed to the  microorganism per se. 
In  the  latter context  it stated as  follows: 
"It is  inconsistent  with  the  Patent  Act  prerequisite of  reproducibility 
of  the  invention to  refer the  expert  to a  product  of  the  inventor 
according  to the  invention  in order  to  reproduce  his  invention. 
Protection for  a  microorganism  per  se or  - what  amounts  to  the  same 
thing  - for  a  process  of  propagating  a  microorganism  in a  conventional - 21  -
manner  without  a  teaching  to  the  expert  as  to  how  to  produce  the 
microorganism  is  so  alien to  conventional  patent  Law  that  it  could  not 
be  obtained via  a  change  in  the  conventional  case  law  but  only  by  a 
22  change  of  the Patent  Act." 
After  the  German  legislature failed  to  react  for  another  eleven  years,  the 
Federal  Supreme  Court  in  1987,  in  view  of  criticism expressed  and  even  more  so 
because of  a  different  view  taken  on  the  specific  issue  by  the  European  Patent 
Office,  reversed  its former  case  Law.  Since  1987,  under  the  German  Patent  Act, 
protection for  a  new  microorganism  per  se  is obtainable,  if the possibility of 
reproducing  the  new  breed  can  be  substituted  by  the  deposit  and  release  of  a 
d  "bl  l  f  h  .  .  23  repro  uc1  e  samp  e  o  t  e  m1croorgan1sm 
The  German  case  law  thus  suggests  that  advances  in protecting biotechnological 
inventions  by  decisions  of  national  courts of  the  Member  States  can  only  be 
expected  after  Long  delays.  Legal  uncertainties  and  deficiencies  of 
protection could,  as  a  rule,  be  remedied  only after years,  perhaps  even 
decades.  Under  the  present  patent  law  regime  in  the  Community,  national 
judicial decisions,  even  those  of  the  Supreme  Courts,  produce  Legal  effects 
only  in  the territory of  that  particular state so  that  favourable  adapation  in 
one  Member  State results  in divergent  adaptation  in  the  Community  as  a  whole. 
Although  case  Law  in  one  Member  State  may  eventually  lead  to  changes  in 
Legislation or  have  harmonising  effects on  the  case  Law  of  other  Member 
States,  no  certainty  can  be  offered with  such  an  approach  and  much  time  would 
be  Lost. 
Cvii)  Necessity  for  the  Community  to  Act 
37.  It  results  from  this  analysis  of  the existing  Legal  framework  at  national 
and  international  Level  <see  (i)  to  (vi))  that  the  Law  for  protecting 
biotechnological  inventions  is unsatisfactory  and  in urgent  need  of 
improvements.  As  a  result of the  work  performed  by  OECD  and  WIPO,  the  main 
deficiencies  have  been  detected  and  recommendations  for  ho~J  to  improve  the 
situation have  been  put  forward.  Particularly the  "Suggested Solutions
11 
elaborated  by  WIPO  accord  with  most  of  the  needs  of  inventors  in  modern 
biotechnology. 
zz;~~~~~~~-~~-~~~~~-~~:-1975, 6  IIC  208  (1975)  - 118aker's  Yeast 11 • 
23occisian of  Febru.1ry  12,  1987,  18  IIC  396  (1987)  - "Rabies  Virus". (:.., ': 
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!;a•.'ing  1·<'~Jar·d  tG  the  grc.'lt  import2nce  of  biotechnolos;/  for·  the  fL•turc  of 
Commcnity,  the  negative effects of  tha divergent  adaptation  resulting  fro~ 
t.iic.:  ~ iq•:;tion  des:-:~ibcd above  arc  unaccP.ptablc  for  the  Corr.munity.  l~hercns  the 
two  Leading  n~tions in biotechnology,  the  United  States of  America  and  Japan, 
h<1ve  been  able  co:.tinuously to adapt  their patent  protection  <Jccording  to  th£· 
l~test needs  of  industry?  science  and  consumers,  the  Member  States, 
representing  comparable  potential  of  intellectudl  manpower  and  capital,  are 
imc~~bilized by  a  not  yet  completed  and,  in  respect  of  biotechnology,  in  P<•rt 
outdated  legal  framework.  In  order  to preclude  any  further  negative  crfects 
for  Community  science,  industry  and  consumers  arising  from  the present 
situation, it  is  incumbent  upon  the  Commission  to  propose  the  nece~;sary 
remedial  measures. 
39.  The  Directive  is also  a  prcrequiste  to  eliminating barriers to  the 
exchange  of  knowledge  and  technology  transfer between  Member  St~tes and  ~o 
trade  in  the  Community.  By  providing  the  same  clear  and  improved  stand2rds  of 
patenting  in  the  national  patent  laws  of  Member  States,  the  readiness  to 
communicate  technical  knowledge,  which  in  the  past  has  suffered  considerable 
setbacks,  will  grow.  In  parallel,  harmonised  protection of  biotechnological 
inventions  will  not  only  give  incentives  necessary  for  investments  in 
biotechnology  throughout  the  Community  but  will  also  cJntributc  to  tr~~e 
between  Member  States  which  under  present  conditions  is  hampered  by  the  fnct 
that  export  of  self-reproducible biotechnological  products  .;nto  areas  with 
uncertain,  weak  or  even  non-existent  protection  is  Less  than  attr·active  for 
obvious  reasons.  Also  as  a  result  of  the  Directive,  the  Community  will  offer 
investors  equal  possibilities  for  protection  so  that  they  may  treat  the 
Community  as  a  single  market  with  the possibility of  securing  reasonable 
returns  on  their  investments.  Community  based  industries will  be  attracted to 
repatriate their  funds  invested  overseas  in  recent  years  in  research  and 
development  in biotechnology.  Investors  from  third countries uill  be  more 
inclined to  invest  in  the  Member  States. 
Relationship between  the  Proposed  Directive  and  the  Europe~~ Patent  Convention 
40.  The  proposed  directive  is  intended  to  coexist,  and  not  to  ir1terfere  with, 
the  existing  intern~tional  Legal  network  in  which  the  EPC,  the  UPOV  Convention 
and  the  Ot•::Jnpest  Treat;;  <.~re  the  cornerstones.  It is  therefor2  incJispt~n:.lhle 
th"t  iJiiJ'  pr·opc:;::Jl  uus"'..  l;c  c·.;:  .• p~t iblc  ~lith the provisions  of  t~:os~  cunven, !uns. - 23  -
Therefore,  the  legislative guidance  offered  by  the  Directive  to  the  Member 
States  having  in  their national  patent  laws  provisions  identical  or  similar  to 
that  of  Article  53  (b)  EPC,  necessarily  takes  the  form  of  provisions  of  a  more 
detailed nature.  This  represents  the only  realistic approach  to providing 
solutions  which  meet  the  needs  of  modern  biotechnology  and  which  establish 
legal  certainty  throughout  the  Member  States. 
41.  The  proposed  Directive  does  not  seek  to  establish  a  Community  industrial 
property  right  for  biotechnological  inventions.  The  proposed  Directive  has, 
however,  methodically  made  use  of existing  Legal  principles  in  patent  laws  and 
Conventions  as  well  as  solutions  developed  in  other  fora  in order  to  secure  an 
application of  national  patent  laws  for  biotechnological  inventions  which  is 
both  necessary  and  appropriate for  the  Community  as  a  whole.  By  harmonising 
national  patent  law  standards  for  the  patenting of biotechnological  inventions 
and  the  scope  of  their protection,  it will  enable  science  and  industry  to 
acquire  in  the  Member  States  one  or  more  national  patents  tailored  to their 
needs  and  the  needs  of  the  consumer.  Since  the  EPC  and  the  CPC  do  not  offer 
the  necessary  legislative protection,  and  due  to  their  coexistence  with  the 
national  patent  laws,  the  Directive  will  fulfil  its tasks  even  after  the  CPC 
has  entered  into  force  in all  Member  States. 
42.  The  proposed  Directive  respects  the  limitations existing under  the 
pertinent  provisions  of  the  EPC  and  the  national  patent  laws  of  the  Member 
States.  It  is therefore  primarily  based  on  the  following  assumptions: 
- discoveries  as  such  are  not  regarded  as  patentable  inventions; 
- plant  and  animal  varieties as  such  or essentially biological 
processes  for  the production  of  plants or  animals  are  excluded  from 
patent  protection; 
- microbiological  processes or  the products  thereof  are eligible  fo~­
patent  protection;  and 
methods  for  treatment  of  the  animal  body  by  surgery  or  t;1erapy  and 
diagnostic  methods  practised on  animal  body  are  not  regarded  as 
inventions  which  are  susceptible of  industrial  npplication  if 
practised for  a  therapeutic  purpose. - 24  -
43.  It  is  clear  thJt  the  framework  of  the  current  rules  on  th~ patenting of 
!ivinn  ~atter nou  reflects  incorrect  assumptions.  In  view  of  the  social  and 
economic  importance  which  biotechnological  inventions  have  for  the  Community's 
future,  the  Directive  provides  for  principles which  will  ensure  that  such 
rules  remain  strictly  limited  to their original  aims. 
44.  For  this purpose  the  proposed  solutions  systematically  take  advantage  of 
work  performed  by  international  organisations  such  as  WIPO,  the  European 
Patent  Organisation  and  OECD.  Particularly the  approach  found  in  the 
Examination  Guidelines  of  the  EP024  and  the  "Suggested  SolutiOflS
11  of  the 
International  Bureau  of  wrro25  form  the  basis  of  or  are  even  in part 
incorporated  in  the solutions of  the  proposed  Directive. 
Since  the  EPO  patent  grant  practice  and  the  Examination  Guide~ines are 
developing  on  a  case-by-case  basis,  reflecting  the  immediate  needs  of  the 
Examining  Division,  they  do  not  address  all  problems  in this  area  or  do  not  so 
in  an  exhaustive  manner.  The  provisions  of  the  proposed  Directive  necessarily 
go  further,  though  generally  in the  same  direction  as  that  originated  in  the 
EPO  Examination  Guidelines. 
Only  in  some  instances,  for  example  in  respect  of  the  availobility of 
deposited matter after the  application  has  been  refused  or  withdr~wn or  is 
deemed  to  be  withdrawn,  the  provisions  of  the  Directive differ  slightly  from 
those  under  Rule  28  of  the  EPC  Implementing  Regulations.  MoreovPr,  the 
Directive specifically addresses  problems  in  respect  of  issues  arising  under 
national  patent  law  only,  such  as  the  scope  of  protection,  rights  conferred, 
infringement  related questions  and  the  like. 
45.  Thus,  on  the  whole  the  proposed  Directive  corresponds  to  the  EPC  and  to 
the  patent  grant  practices of  the  EPO.  Although  it will  not  directly or 
legally affect either the  EPC  or  the  practice under  the  EPC,  the  indirect 
effects of  the proposed  Directive  should  be  substantial. 
24  Guidc1.ines  for  ExaminJtion  in  the  European  Patent  Office,  published 
by  the  Europenn  Pa:rmt  Office,  ~1unich  1-?85,  as  Last  amended  in  July  1937. 
25  Contnined  in  WIPO  Doc.  BIOT/CE/III/2  of  April  8,  1987. - 25  -
Firstly, as  far  as  the  Directive  correlates  with  the  existing patent  granting 
practice  based  on  the  EPO  Examination  Guidelines,  it will  in fact  le~d  to~ 
harmonised  interpretation of  European  and  national  patents. 
Secondly,  Yhere  provisions of  the  Directive  clarify questions  not  yet  answered 
in the  Examination  Guidelines  of  the  EPO,  they do  so  with  the  necessary 
legisLAtive authority and  closely  following  the  solutions  suggested  by  the 
International  Bureau  of  WIPO.  This  will  facilitate the  task  of  the  EPO  in  its 
constant  efforts  to  improve  on  firm  grounds  its  Examination  Guidelines.  For 
it is virtually excluded  that  national  administrative or  judicial authorities 
of  the  Member  States,  competent  for  example  in  revocation procedures,  will 
take  an  approach  for  European  patents different  from  that  for  national 
patents,  although  they  would  have  been  issued on  the  basis of different  but 
analogous  provisions. 
As  regards  the differences  in  respect  of  the  availability of  the deposited 
biological  materials,  the  proposed  Directive  does  not  interfere  with  the  EPC. 
It only  provides  for  har~cnised solutions  in  national  patent  laws  of  the 
Member  States,  which  under  the present  regime differ  among  themselves  as  well 
as  with  regard  to  EPC  Rule  28. 
A possible effect of  the  proposed provisions  of  the  Directive  which  differ 
from  EPC  Rule  28  could  result  in  an  adaptation of  that  Rule  to  the  Directive. 
Such  an  amendment  could  be  provided  for  by  agreement  between  the 
Administrative  Council  of  the  Europe~n Patent  Organisation,  without  revising 
the  EPC. 
46.  Fro~ the  foregoing  it is clear that  the  proposed  Directive will  not 
interfere with  the  EPC,  nor  will  it establish  any  interdependence  inn  legal 
sense  between  the  two  bodies  of  law.  The  practical  interaction of  the  two 
systems  is nonetheless  likely to be  productive.  On  the  one  hand,  only  the 
Directive  is in  a  position  to  secure a  harmonised practice under  the  EPC  as 
far  as  the national  phase  of  th~t practice  in  the  Member  States  is  concerned. 
On  the other i.and,  the  Directive uill  offe~ the  EPO  firm  grounds  on  which  to 
develop  further its patent  granting practice  according  to the  latest  needs  of 
industry  nnd  science  in biotechnology. - 26  -
Relationship between  the  Patent  protection under  the  Proposed  Directive  and 
the  Protection of  Plant  Breeders'  Rights  under  the  UPOV  Convention  and 
National  Plant  Varieties  Laws 
47.  The  proposed  Directive will  not  fetter  the  principles or  the  working  of 
either the  plant  breeders'  system  or  the  UPOV  Convention.  The  principle of  the 
prohibition of  double  protection,  i.e. protection  by  plant  breeders'  rights 
and  patents  for  the  same  botanical  genus  or  species,  as  established  under 
Article  2  .(1)  UPOV  Convention,  is no  longer  uniformly  applied  in  the 
Convention  itself26  and  is also very  much  in dispute.27  Nonetheless,  the 
Directive  Leaves  that  principle untouched. 
Notwithstanding  extensive  criticism of  certain  UPOV  principles  by  major  users 
of  plant  variety  protection based  on  the  UPOV  system,  an  approach  directing 
the  Member  States  to  revise  the obligations  into  which  they  entered  under 
international  conventions  outside  of  the  Community  legal  framework  appears 
inappropriate  for  the  moment.  Moreover,  certain positive effects,  in  part 
experienced  with  plant  breeders'  rights  in  the  Community  Member  States  which 
are  also  members  of  the  urov28,  in  those  areas  of  plant  agriculture  in  which 
such  rights  are effectively available29,  leads  to the  conclusion  that  a 
restrictively applied  exclusion  of  patentability of  plant  varieties  as  such 






Exceptional  Rules  for  protection under  Two  Forms,  Introduced  into  the 
UPOV  Convention  by  the  1978  Revision  (Article  37  (1)  allow,  under 
certain conditions,  Member  States or  adhering  States  to grant  plant 
breeders'  rights  as  well  as  patents  for  the  same  botanical  genus  or 
species.  So  far  the  United  States of  America  has  taken  advantage  of  this 
possibility.  The  US  Patent  and  Trade  Mark  Office  (PTO)  thus  grants  patents 
for  plant  varieties  regardless  of  whether  they  are eligible for  special 
plant  variety protection established along  the  lines  of  the  UPOV-Convention 
<Decision  of  the  PTO  Board  of  Appeals  and  Interferences  of  September  24, 
1985,  227  USPQ  443  -ex parte  "Hibberd"). 
Proposals of  International  Non-governmental  Organisations  for  Revision 
of  the  Convention,  Document  UPOV/IOM/III/3. 
Greece,  Luxembourg  and  Portugal  are  not  members  of  the  U?OV. 
The  UrOV  Convention  allows  its contracting States  to  Limit  protection  to 
only  a  minimal  number  of  genera  or  species  of  plants,  i.e., States must-
after eight  years  of  memberhip,  protect  at  least  24  (Article  4  (3)(b)(iii). 
As  a  result  of  this principle,  even  in  the  Community  Member  States 
belonging  to  the  UPOV,  extensive areas  of  plant  agriculture  are  not 
covered  by  UPOV-type  plant  breeders'  rights. - 27  -
For  it  is  tl1e  modern  plant  biotechnology  which  offers  the  pro~r~cts to 
eventually  ov~rcome problems  with  which  Community  agriculture  is  faced  and 
which  therefore  merits  the  best  possible  incentives.  Farmers  througl1out  the 
Community  are  in great  need of  new  products,  commercially desirable  as  well  as 
environmentally  acceptable,  which  traditional  plant  breeding  techniques  are 
not  able  to  produce.  Modern  plant  biotechnological  processes,  for  example  for 
transferring  foreign  genes  into plant  cells or  for  regenerating  transformed 
cells  into  whole  plants etc.,  as  well  as  products  thereof,  such  as  genetically 
modified  plant  cells, plant  cell  lines, plant  tissue  culture  and  transgenic 
plants,  must  be  offered the best  possible protection  in  order  to provide  the 
incentives  necessary  to mobilize  intellectual  manpower  and  to  induce  capital 
investment  to  the  extent  necessary to maximize  the  innovatory  potential  in  the 
Community's  agricultural  sphere. 
48.  The  UPOV-type  protection  which  is at  present  available does  not  offer 
appropriate  incentives.  For  example,  it does  not  cover  process  innovation.  In 
addition,  the  scope  of  protection provided  for  products  encompasses  only  the 
production  and  commercialization of the  reproductive  or  propagative material, 
as  such,  of  the  protected variety,  but  not  whole  plants or parts  of  plants, 
such  as  cut  flowers,  as  end  products.  ~astly, and  far  more  importantly,  plant 
breeders'  rights  are  governed  by  the  principle of  independence:  no 
authorization  is  required  from  and  no  licence  fees  are  paid  to the original 
breeder  for  the  use  of  his  protected variety  as  a  starting base  for  breeding 
and  commercialising  new  varieties.  Although  this  rule  was  designed  to 
facilitate  improvement  of  plant  genetic diversity,  it was  and  remains,  in  its 
broad  form,  an  insufficient  incentive  to  lead  to  investments  in truly  new 
developments. 
Distinctness,  a  criterion for  protection of  new  varieties,  as  applied  under 
the  UPOV  schc~:~ does  not  focus  on  characteristics essential  for  the  working 
(functioning)  of  a  plant variety.  The  rule of  independence  seems  to  have 
resulted  in  investmer.t~ to achieve  ~inimal variations of  existing varieties, 
rather  than  in  rr~earch and  development  of  genuine  improvements  in genetic 
diversity.  Traditio~al breeding  methods,  supported  by  plant  breeders'  riqhts, 
were  not  Jble  •o  pr?vent  the  present  situation  in  Community  agricultur~ in 
which  the  CEC  i~  unable either  t0  corJsume  or to sell all that  it produces. - 28  -
Biotechnological  methods  for  developing  new  plant  products  offer genuine 
promise  for  producing  commercially  desirable  and  therefore  saleable 
agricultural  materials. 
In  this  connection  a  recently established  "Committee  on  a  National  Strategy 
for  Biotechnology  in Agriculture" of  the  US  National  Research  Council -a body 
of  the  National  Academy  of  Sciences  since  1916  - recommends  in  its 1987  report 
on  ''Agricultural  Biotechnology"  inter alia: 
"Patenting and  Licensing  play necessary  roles  in  advancing  technology 
transfer  and  assuring  the  commercialisation of  research  results, 
especially  in  capital  intensive  fields  such  as  biotechnology.  Patenting 
and  licensing  by  universities  and  government  agencies  should  be 
encouraged  as  key  instruments  used  to  transfer technology.  Universities 
and  government  agencies  should  provide  incentives  to their  scientists to 
encourage  patenting.  Public  policy  should  encourage  state  land-grant 
universities  to  confer  exclusive  licences on  patents  to private 
companies  with  the  resources,  marketing,  and  product  interests  required 
to translate these discoveries  into  commercial  products.1130 
The  Committee  in effect  is  recommending  no  Less  titan  a  complete  departure  frum 
a  policy  followed  for  decades  in  US  agricultural  economics  which  generally 
opposed  exclusive  rights  in  the  field of  publicly  funded  agricultural 
research. 
49.  The  principles of  the  UPOV  Convention  as  applied  in  the  national  laws  of 
the  Member  States will  be  unaltered  by  the  proposed  Directive.  Nonetheless  it 
is  indispensable  to  secure  the  undisturbed  functioning  of  the  patent  system  in 
areas  clearly allocated for  patent  protection,  that  principles  necessary  to 
clarify the  interrelation of  the effects of  patents  and  plant  breeder'  rights 
be  adopted.  The  pertinent  provisions  of  the  Directive  safeguard the  necessary 
contents of  patent  rights,  taking account  of all  the  relevant  interests 
involved,  including  science,  industry,  breeders,  growers,  farmers,  taxpayers 
and  consumers. 
------------------------ 30  Agricultural  Biotechnology  - Strategies for  National  Competitiveness, 
Washington,  D.C.,  1987,  14. - 29  -
Legal  Basis 
50.  In  the  White  Paper on  completing the  Internal  Market  under  "Creation of 
Suitable  Conditions  for  Industrial  Cooperation"  the  Commission  gave  clear 
notice  of  its intention to propose  to the  Council  specific measures  to  improve 
patent  protection of biotechnological  inventions  in  light of  the negative 
impact  which  differences  in national  laws  have  on  intra-Community  trade  and  on 
the ability of  industry to treat  the  common  market  as  a  single environment. 
The  present  proposal  therefore  forms  part  of  the  Commission's  programme  for 
the  completion of  the  internal  market  before  31  December  1992. 
For  the  achievement  of  the  internal  market  before  31  December  1992,  Article 
100A  paragraph  1,  sentence  2  provides  by  way  of derogation  from  Article  100: 
The  Council  shall,  acting by  a  qualified majority on  a  proposal  from  the 
Commission  in  cooperation  with  the  European  Parliament  and  the  Economic 
and  Social  Committee,  adopt  the  measures  for  the  approximation  of  the 
provisions  laid down  by  law,  regulation or administrative action  in 
Member  States  which  have  as  their object  the  establishment  and 
functioning  of  the  internal  market. 
Article  8A  paragraph  2  defines  the  internal  market  as  comprising  "an  area 
without  internal  frontiers  in  which  the  free  movement  of  goods,  persons, 
services  and  capital  is ensured  in  accordance  with  the provisions  of  this 
Treaty."  Differences  in  industrial  property  laws,  such  as  exist  in  national 
patent  laws  in  Member  States  as  regards  biotechnological  inventions,  hamper 
the  proper  functioning  of  the  internal  market.  The  present  proposal  will 
establish equal  possibilities for  protection of  the  results of 
biotechnological  research  and  will  thereby  create  a  legal  framework 
facilitating  cooperation between enterprises.  In  addition,  the  Directive will 
produce  suitable conditions  for  the exploitation of  the  results  of  such 
research  and  will  encourage  ·industrial  development  and  greater 
intra-Community  trade. 
Industry  in  those  countries  with  clear  and  established practices  of 
patentability and  patent  procedure  is  in  a  more  favourable  position  than  that 
in countries  where  practices  have  yet  to  be  established and  where  insufficient - 30  -
experience  has  resulted  in  an  uncertain situation for  the  protection of 
biotechnological  inventions.  Such  differences distort  the  conditions  of 
establishment  and  of  competition  in  Member  States  for  firms  which  engage  in 
activities  concerned  with  biotechnology.  The  development  of  a  Community 
biotechnology  industry  as  a  whole  is hindered.  In  consequence,  the  common 
market  fails  to develop  as  it should  for  its proper  functioning. 
By  providing  the  conditions  for  the  results of  research  to be  legally 
protected ·on  a  uniform  basis  in the  Member  States,  innovation  and  technical 
progress on  an  EEC  scale will  be  encouraged. 
The  Directive will  also  foster  a  greater movement  of  biotechnological  goods 
between  Member  States because  the  reluctance  to engage  in  inter-State trade 
which  results  from  a  lack of protection  in one  or more  Member  States will  be 
eliminated or will  not  arise if  legal  protection is  clearly available  on  an 
equivalent  level  in all  Member  States.  Without  the  improvement  in protection 
and  legal  certainty anticipated by  the  Directive, offers  for  sale of  many 
future  biotechnological  products  would  not  be  made  in some  Member  States  and 
the  enforcement  of national  patent  rights  in a  Member  State where  protection 
existed  agai~~t  imports  from  a  Member  State  where  no  protection  was  available 
could prevent  the  creation of  the  conditions  necessary  for  the  proper 
functioning of  the  common  market.  The  free  movement  of  goods  could be 
adversely affected due  to  a  variable  system  of  national protection  in  the 
Member  States. 
Nothwithstanding  the benefits to the  internal  market  which  would  result  from 
the  entry  into  force  of  the  CPC,  unlikely  in  any  event  before  1993, this 
Convention  will  be  limited to patents granted  under  the  European  Patent 
Convention  only.  In  consequence,  the national  systems  of patent  law  would  be 
unaffected  by  the entry  into  force  of  the  CPC.  Thus,  th~re remains  a  need  for 
an  instrument directed to the national  patent  systems  which  encourages 
biotechnological  research  in  Europe  with  a  reasonable  expectation,  if desired, 
of  protecting such  work  via  the  national  patent  systems.  This  in turn will 
ensure  that  both  a  Community  biotechnological  industry  and  Community  trade  in 
biotechnological  products  develop  as  necessary  for  the  proper  functioning  of 
the  common  market. - 31  -
In  the  preparation of  this proposal  the  Commission  has  taken  into account  the 
requirements  of  Article  Be  of  the  Treaty  and  has  concluded that  no  special 
provisions or derogations  socm  warranted or  justified at  this  stage. 
Likewise  the  Commssion  has  studied the  ~uestion of  the  high  level  of 
health/safety/environmental  and  consumer  protection  required  by  the terms  of 
Article  100A(3)  of  the  Treaty.  In  the preparation of this proposal,  full 
account  was  taken of  these considerations  which  are directly dealt  with  in 
other  Community  instruments~ - 32  -
PART  TWO:  . PARTICULAR  PROVlS.IONS 
CHAPTER  1 
Patentabi l"ity of  Living Matter··· 
-· 
Article 1 
This  Article defines  the  aim  of  the Directive:  to ensure  that  national  patent 
laws  are  in compliance  and  accord with the terms  of  the directive.  The 
Directive will  hnve  no  legal  effects vis-a-vis  the  European  Patent  Convention 
<EPC)  or  any  provisions thereof. 
Article 2 
The  aim  of  Article 2  is to establish  legislatively that the  condition of being 
alive or of  being  living matter  would  be  legally  insuf-ficient  to  render  such 
' 
material  unpatentable.  This  principle must  be  explicitly  reco~ni~~~ for 
biotechnological  inventions.  The  normal  criteria for patentability provide  no 
guidance  on  how  to determine  the patentability of  living matter.  This  article 
is therefore  necessary  even  though  the principle to be  established is already 
'  widely  recognised.  Where  the principle  is not  completely  accepted;-under 
Article 2,  the argument  can  no  longer  be  raised that all  living matter must  be 
excluded  from  patent  protection on  the ground  that  the  mere  fact  of  being 
alive disqualifies such  inventions  from  being  regarded as patentable, e.g., on 
the basis  that they  are natural products. 
The  history of  industrial property protection demonstrates that  inventions in 
newly  developing  technologies  have  always  encountered difficulties  in  securing 
Legal  protection.  Such  an  explicit  legislative provision as  is  laid down  in 
Article  2  is necessary  to  remedy  certain  diffi~ulties and  to prevent  others 
from  arising  when  general  provisions of  patent  law  are applied to inventions - 33  -
involving  technology  that  makes  use of  living entitites such  as  animals, 
plants  and  micro-organisms.  As  all  inventive activity  involves  intervention 
by  man  into  the processes or  products  of  nature,  there  is no  reason to exclude 
from  protection  inventive  a~tivity relating to  living  ~atter, other than the 
area of  humankind  (but  this.~ype of  provision  is already  commonplace  in patent 
law  o~ public policy grounds •s is found  in Article  52{4)  EPC>. 
Only  a  very  few  national  courts of  the  Member  States, after decades  of 
uncertainty,  have  managed  to develop  a  coherent doctrine under  patent  Law  to 
protect  living matter.  Article 2  will  establish a  minimum  Level  of  legal 
certainty without  the delay  caused by  awaiting  judi~ial resolutions  which  may 
not  arise.  Such  certainty is required to foster  economic  and  technical 
progress.  This  can  only be  achieved  within  an  acceptable period of  delay  by 
requiring  Legislative  adoption of  the  rule  to  recognise  the general  rule  that 
living matter  as  such  is no  less patentable  than  non-living  ~atter if the 
required  extent· of  novelty,  inventive  a~tivity and  industrial applicability is 
present  for  patent  law  purposes. 
Article 3 
Although  biotechnology is an  old science  involving  the use  of  and  deliberate 
selection by  man  of organisms  which  improve  agriculture,  animal  husbandry  and 
baking  and  brewing activities,  research  in the  new·  areas  of  biotechnology  is 
producing  an  even greater ability on  the  part  of  man  to  intervene  in natural 
biological  processes.  When  attempt  is made  to determine  the extent  of  patent 
protection which  might  be  available to  inventions  in the  field of  Living 
matter,  there  is  the additional  complication of  a  special  system  which  was 
devised  for  the protection of  plant varieties.  The  existence of this special 
system  has  generated uncertainty as  to the  extent  to  which  plant  matter  as 
such  can  be  patented. 
Biological classification begins  with  the  kingdom  descending  from  the phylum 
through  the genern  and  species.  All  members  of  genera  and  species possess at 
least  some  common  characteristics but  also usually possess  other 
characteristics which  distinguish  some  members  from  others.  A variety, 
however,  for  purposes  of  variety protection,  is defined  as  a  group  whose 
members  possess  no  distinguishing characteristics one  from  another. - 34  -
Exceptions  to  patentability for  the  categories  of  inventions  relating to plant 
and  ani~al varieties  ~nd essentially biologicDl  procasses  for  producin~ plant9 
and  animals  were  created under  certain conventions  on  the  ba~is that  thc~c 
i~v2ntin~s lacked  industrial npplicability.  It uns  considered  prefcr~blc to 
provid~ special  protection  for  plnnt  varieties  soma  of  which  were  alreajy 
pntented  and  p~tcr1table  1n  vJriou~ countriPs.  For  animal  varieties,  the need 
for protection  was  less  rvident  an~  ~herefore patent  protection  was  not 
serio~sly considered. 
It  is clear  today  that  the  new  biotechnological  techniques,  which  were  unknoun 
to  the  authors  of  the  relevant  exclusions,  have  come  to occupy  the territory 
of  both  fields.  This  is demonstrated  by  the  numerous  developments  which  have 
arisen  in  microbiology  which  now  lead to the  development  of  new  plant  and 
animal  characteristics.  No  justification appears  to exist  at  present  to 
continue  to treat the  results  of different  forms  of  research differently as  to 
the protection  which  may  be  obtained.  Thus,  were  patent  and  plant  variety 
protection systems  being  formulated  on  the basis of  current  scientific 
developments  and  technology,  different  provisions  for  these  ~ystems might  be 
adopted  from  those  chosen thirty years  ago.  Nonetheless,  until  the 
international  legal  framework  can  be  adapted  to  the  new  technologies,  these 
exclusions will  remain  and  must  be  addressed  if greater  legal  clarity and 
certainty are  to  be  achieved. 
The  exclusion of  plant  and  animal  varieties  prohibits  only  the  patenting of 
a~imals, plants  and  plant  propagating material  in the genetically  fixed  form 
~ 
of' a  plant  or  animal  variety.  There  is no  justification where  an  invention 
concerning plant  or  animal  matter,  such  as  plant  or animal  cells,  cell  lines, 
tissue  cultures  and  larger parts,  is not  covered  by  the  language  of  the 
exclusion to either withhold protection from  such  an  invention or  to give  the 
exclusion  a  wider  interpretation than  is justified by  the  purpose  for  which  it 
was  developed.  It  is perfectly acceptable  and  appropriate for  the exclusion 
to be  limited,  in  conformity  with  its wording,  to those  cases  in which  plants 
are  characterised precisely by  their individual phenotype.  Article 3  first 
sentence  therefore  provides  that it is not  plants  and  animals  in general  which 
are  excluded  from  patentability but  only plant  and  animal  varieties as  such, - 35  -
i.e.  in the genetically fixed  and  stable  form  of  a  variety.  Thus,  Article  3 
first  sentence  will  establish  the principle that  patent  protection  is 
available  for  plant  and  animal  material  which  is not  a  variety. 
The  second  sentence of  Article  3  is necessary  as  regards plants  in  light of 
the uncertainty created by  Article 2(1)  of  the  UPOV  Convention  which  oblige~ 
contracting States to provide only  one  form  of  legal  protection for  the  same 
genus  or  species.  The  principle  is clear  that  if plant  variety protection  is 
available  for  a  variety, patent  protection would  not.  But  if patent 
protection  is available  for plant  material  which  is not  a  variety,  as  is 
required  in the first  sentence  of  this Article,  the  rule must  be  legi~latively 
clarified as  to  how  far  the patent  rights extend.  Thus,  this  sentence 
acknowledges  the  principle that  protected plant varieties must  co-exi~t 
alongside patents on  plants  but  requires  the  further  principle to be 
introduced that  the  patent  rights pertaining  to  such  patent  ~Laims must  be 
enforceable  even  in  respect  of  finished varieties  incorporating  such  patented 
inventions. 
Without  Article 3,  the  patenting of  new  plant  characteristics,  such  as  insect, 
disease  and  herbicide  resistance, might  not  be  given  the  proper  Legal  effects 
which  encourage  economic  progress  via  the  patent  system.  Article  3  in  no  way 
interferes  with  the  role or the  legal  effects of  the  system of  breeders' 
rights  •  However,  problems  of  interaction between  exclusive  rights  granted 
under  the  patent  and  plant  breeders'  systems  may  arise where  the patentability 
of plants, parts of plants  such  as  genetic  sequences  and  classifications other 
than  varieties is  recognised.  The  legal  uncertainty which  is thereby  created 
relating to the extent  of  the  rights  which  may  be  enforced  between  the  two 
systems  must  be  resolved.  Article 3  is therefore necessary to ensure  that  the 
patent  system  is allowed to produce  its proper effects without  hindrance  from 
or _to  the plant  breeders'  system.  Article  3  is also necessary  to  respond  to 
the  need  to determine  the  effect of  patent  rights  in  any  invention  relating to 
plants  which  is subsequently  incorporated  into a  variety and  which  variety is 
subsequently protected by  a  plant  breeders'  right.  Article 3  establishes  the 
principle that  in  such  a  case  the  patent  rights  would  remain  effective as  to 
the patented  invention. - 36  -
Article  2<1>  of  the  UPOV  Convention  directs  the  contracting States  that  they 
may  accord only  one  form  of protection  to  any  protected genera or  species. 
This  menns  that  both variety protection and  patent  protection  <double 
protection)  cannot  be  granted to the  same  plant  genera or species.  Article  3 
ensures  that  a  clear  borderline  is drawn  between  protectable  subject  matter  in 
each  system.  One  may  take  as  an  example  a  genetic  sequence  inserted  into the 
genetic material of  a  plant  which  r!nders  the plant  resistant  to insects.  The 
genetic  sequence  is patented  and  is subsequently  incorporated  into an  existing 
vari0ty.  ·The  new  variety  now  possesses  the  new  characteristic  and  is eligible 
for  variety protection.  There  is no  reason  for  such  a  new  variety to be  free 
from  the effects of  the  patent.  This  would  effectively deny  the  inventor  of 
the  legitimate  scope of  the right  to  his  invention. 
Such  an  approach  neither  jeopardises nor  runs  contrary  to the principle of 
Article  2<1>  UPOV.  It is not  the genetic  sequence  which  is protected by  the 
plant  breeders'  right  nor  is  the variety protected  by  the  patent.  There  is  no 
requirement  in either patent  law  or  in plant  variety  law  that  the  patent 
rights associated with  a  patented  invention  are  extinguished  simply  because  a 
variety  right  is also associated with  the  final  product.  Nor  do  any 
compelling  polic~ reasons  exist  for  such  an  interpretation.  Quite  the 
contrary.  future  developments  in biotechnology are  likely to provide  a 
valuable  range  of  new  and  enhanced  agricultural  products  incapable  of  being 
produced  under  traditional breeding  techniques  which  will  have  a  ready  market 
demand.  It is also foreseeable  that  new  agriculture products  will  be 
developed  that  have  new  industrial applications,  for  example,  as  petrochemical 
substitutes and  in the field of  polymer  chemistry. 
Notwithstanding  the historical  context  and  logical  inconsistency of  present 
plant  variety and  patent  laws,  the  Commission  considers  that  it would  be 
harmful  neither to the interests of  European  industry engaged  in 
biotechnological  research  nor  to the purposes  for  which  the directive  is 
designed to allow  a  certain number  of  cases,  likely to have  applications as 
plant varieties,  which  would  otherwise  have  been  patentable,  to be  excluded 
from  patentable subject matter  under  national  patent  laws  when  such  plants 
have  been  produced  by  a  known  biotechnologial  process.  The  principle of 
Article  3<2>  is necessary  to ensure this result. - 37  -
Article  4 
Patent  Law  traditionally recognises  three  types  of  protectable  inventions: 
process  inventions,  product  inventions  and  application  inventions  (also  cnlled 
''uses">.  The  corresponding categories of  patentable biotechnological 
inventions  would  be  identified as: 
1)inventions  relating to a  process  for  the  creation of  a  Living  organism 
or  the  production of other biological material; 
2)inventions  relating to an  organism or material  as  such;  and 
3)inventions  relating to the  use of  an  organism or other biological 
material. 
As  most  Member  States  have  explicitly excluded  from  patent  protection plant 
and  animal  varieties as  such,  the result  is that  plant  and  animal  varieties as 
products  are  not  eligible for  patent protection.  This  does  not,  however,  have 
the effect of excluding the other two  types  of  iriventions  from  protection if 
and  as  these  relate  to plant  vnricties,  that  is, microbiological  processes  and 
processes  which  are not  "essentially biological"  for  the  production of  plant 
varieties  and  specific  uses  of  plant varieties.  Article  4  is needed  so that 
these  two  types  of  inventions  are  expressly  included  in  protectable  subject 
m0tter  under  the patent  laws  of  the  Member  States. 
Article  4  will  thus  establish  the principle  in  national  patent  Laws  that  the 
traditional  ~ategories of  patentable  inventions  relating to processes  and  uses 
are  not  affected by  the  exclusion of  plant .and  animal  varieties  from  patent 
protection.  In  Light  of the_exclusionary  provisions of  many  patent  Laws  along 
with  th0  princ~ple of  the  prohibition of double  protection  in  Article  2<1>  of 
the  UPOV  Convention,  Article 4  in  necessary to establish clearly that  the 
traditional  caiegories of patentable  inventions  as  these  relate to 
biotechnological  inventions  constitute patentable subject matter. 
Article  5 
Most  Member  Status'  nationnl  patent  laws  mirror  the  language  of  Article  53(b) 
of  the  European  Potent  Convention  ~hich states that  patents shall  not  be 
granted  in  ~c~pect of - 38  -
.  ,  '  .  . 
plant  or  animal  varieties or  essentially .biological  processes  for  the 
production of  plants  or  animals;  this provision does  not  apply  to 
microbiological  processes or  the  products  thereof. 
Thus,  when  the  exclusions  for  plant  and  animal  varieties  and  essentially 
biological  processes  were  drafted,  the  field of microbiology,  which  did not 
involve  traditional  breeding  processes,  was  singled out  as  being  appropriate 
for  patent  protection.  Microbiological  processes  and  products  of  such 
processes·were  specifically  recognised  as eligible  for  patent  protection.  The 
underlying  motivation  for  this  language  was  to  carve  out  of  patent  law 
protection the  results of  traditional  breeding  processes  using  plants  and 
animals.  The  results  of  such  breeding  processes  would  enjoy  their  own 
protection  in  the  form  of  plant or  animal  variety  rights. 
Because  inventions  relating to living matter  specifially resulting  from 
microbiology are patentable  in those  Member  States  with  such  provisions, it is 
therefore of  considerable.importance  for  the  application of patent  law  to 
establish  what  is  included  in the term  "microbiological  process".  Where  the 
determination  of  the  patentab~lit~ of  a  biotechnological  invention  rests  on 
the  criterion of  whether  a  process  is microbiological,  it  is vital  to  a  proper 
application.of  patent  Law  that this term  be  correctly defined.  Article  5 of 
the  Directive  addresses  this problem  and  establishes  a  minimum  principle  in 
this  respect. 
No  attempt  was  made  to  specify  the  borderline  between  those  areas  capable  of 
patent  protection  - microbiological  processes  and  products  - and  those areas 
excluded  from  protection - plant  and  animal  varieties and  essentially 
biological·p~ocesses- it  b~~ng assumed  that  the  results of traditional 
breeding  and  microbiological  proce~ses would  be.readily distinguishable.  Had 
science  and  biotechnology not  made  the  advances  they  have  in the past thirty 
years,  these distinctions  would  continue to be  valid and  the  two  types  of 
protection  would  have  wholly  separate fields of  application. - 3~'  -
As  many  inventions  in  the  field of biotechnology  concern  micraorganicm~, the 
principle of  pat~nt  law  in  Article 5  in  respect  of  ~icrobiolcgical  proces~es 
corrcs~onds best  to the tiriginal  intentions of  the  dr~ftefs ~f  the  exclusion~, 
accords  with  the  exclusions  ~1hich hove  been  adopted ahd  of~ers an  tadequ!ltr: 
incentive  to potential  innovators to pursue high  risk :and  co.stly  research. 
Without  this  Article,  it would  be  possible  for  widely  varying definitions to 
be  adopted  throughout  the  Community  of  what  is considered microbiological  and, 
consequent-ly,  for  very different decisions  to be  taken  regarding  the  same 
factual  patent  application.  Article 5  is  therefore necessary  to establish a 
minimum  uniform principle of patent  law  and  at  the  same  time  avoid  an 
inappropri:)tely  narrow  JJrinciple  froo  being  adopted  in  connection  with  the 
patent  law  toncept  of  "a  microbiological  process".  Thus,  the  rule must  be 
established that  inventions  relating to processes which  either use  or directly 
operate  upon  or  result  in  a  ~icroornonism should  be  ~onsidered microbiological 
and  thus  eligible for  patent  protection.  Article  5  prescribes this  rule.  In 
this  connection,  Article  5  must  be  read  in  conjunction  with  Article  19 of  what 
sholJld  be  understood  by  the  term  "microorganism".  Thus  the principle of 
Article  5  would  not  be  limited only  to microorganisms  as  such  but  would  apply 
to other microscopic  animate  matter  as  well. 
Article  6 
Likewi~P greater  certainty and  uniformity  must  be  engendered  into  the 
application of  the  criterion  in national  patent  laws  of  the patent  law  concept 
of  a  ''microbiologic~l process".  To  give  optimum  effect  to developments  in 
biotechnology,  it must  be  legislatively established that neither the entire 
process  nor  every  step  in  the  proces$  need  be  of  a  microbiological  nature  in 
order  for  the  process  as  a  whole  to be  deemed  microbiological.  If  a  necessary 
and  important  part  of  a  complex  process  is microbiological,  while  other steps 
of  the  process are  merely  biologicnl,  rejections of patentability on  the basis 
that  the process  is essentially biological  should be  prevented.  Article 6  is 
necessary  to  produce this  result. - 40  -
The  Article  will  make  it necessary  for  the  principle to  be  adopted  that  a 
multi-step  process  in which  the  essence of  the  invention  is  incorporated  into 
a  microbiological  step  is  not  deprived  of  its microbiological  character  simply 
because  the  process  contains other,  non-microbiological,  steps.  To  take  an 
example,  the  genetic  manipulation  of  a  plant  cell  may  be  performed  which  is a 
microbiological  process.  Thereafter,  the entire plant  may  be  regenerated  from 
the single cell  <a  process  called differentiation).  This  latter process  may  be 
said to  be  essentially biological,  but  the entire process  should  be  accorded 
the  charac~er of  microbiological  because  the  essence of  the process  and  the 
invention  is  a  microbiological  step.  The  process  should therefore be 
considered  patentable despite  the presence  of  an  essentially biological  step 
in  the  overall  inventive process.  Without  Article 6,  the exclusion  from 
patentability of  essentially biological  processes  for  the  production of plants 
could  result  in  erroneous  rejections  to patentability and  unsystematic 
adaptation  of  national  patent  law  principles when  applied  in  the  same  factual 
contexts. 
Article  7 
Because  some  national  patent  laws  exclude  essentially biological  processes 
from  patentability,  it  is necessary  to  lay  dow~ a  principle of  patent  laws 
which  establishes the  extent  to which  human  intervention is  required  in order 
to  ensure  that  an  invention will  be  considered patentable subject  matter.  In 
this  connection,  it is  important  to distinguish  between  traditional  breeding 
activities and  other  forms  of  human  intervention  in biological matter.  As 
essentially biological  processes are generally agreed  to  refer  to traditional 
breeding  processes,  it  is  important  that  the principle  laid down  differentiate 
betueen  the  use of  biological material  which  falls  into  the  category  of 
essentially biological  and  that use  which  may  properly be  regarded  as 
patentable subject  matter. 
The  EPO  Examination  Guidelines stipulate in this  regard  that  human 
intervention must  play a  "significant part"  in determining or  controlling the 
result  it  is desired  to achieve  and  notes  that  the  question is one  of  degree 
depending  on  the extent  to  which  there  is technical  intervention  by  man  in  the - 41  -
process  CC-IV,  3.4).  Article  7  of  the  Directive,  by  contrast,  is  intended  to 
exclude  only  traditional biological  breeding activities based  upon  selection 
and  as  such  may  be  regarded  as  slightly more  liberal  than  the  Guidelines. 
Article  7  will  ensure  that  both  an  appropriate  and  a  consistent  rule  is 
adopted  for  national  patent  systems  in situations  where  it needs  to  be 
determined  if sufficient  technical  human  intervention has  occurred  to  render 
an  invention patentable.  Such  a  rule  should  reflect  a  liberal  approach  in 
view  of  the  now  artificial nature  of  the distinction between  "essentially 
biological"  and  ''not  essentially biological"  processes.  Biotechnological 
techniques  have  effectively  rendered  this difference of  little practical 
value.  Thus,  for  purposes  of  national  patent  Laws,  human  intervention of  a 
technical  nature  into the  natural  processes of  biology need  not  be  at  the  same 
time  of  a  drastic nature  in order  for  a  process  to fall  outside  the  scope  of 
being  "essentially biological".  Any  human  intervention  aside  from  selection, 
such  as  influencing  the  crossing  procedure  or  the  replication process,  would 
remove  the  process  from  the  field of "essentially biological"  processes.  The 
invention  would,  of  course,  thereafter fall  to be  considered under  the 
criteria for  patenting. 
Article 8 
In  certain  circumstances,  patent  law  recognises  the patentability of  products 
or  substances  which"are  of  natural origin.  Usually this occurs  in situations 
where  a  product  exists  in  a  naturally occurring  mixture  of  substances  without 
it having  been  identified  in  the mixture.  The  invention typically consists  of 
identification of  the  substance  and  isolation for  useful  purposes  in  a  usable 
or  pure  form  in which  it did  not  exist  in nature. 
With  the  new  biotechnological  techniques,  many  substances  are  now  capable  of 
being  selected and  adapted  for  industrial,  commercial  and  medical  uses.  The 
possibility of  legally protecting such  developments  in  the field  of 
biotechnology  is  important  to ensure  that  the  necessary  investment  and 
research  are  undertaken. - 42  -
Not  all  national  patent  systems  have  recognised  the patentability  of  naturally 
occurring  matter  which  fulfils the criteria for  patentability,  such  as  that  in 
a  mixture  (either natural  or  modified)  notwithstanding  the  fact  that  the 
substance  existed  in  an  unidentified  form  prior  to the  recognition of  its 
existence  and  utility and  prior  to adapting  the  matter  for  use  in  an 
industrial  application.  Article 8  will  establish that,  as  long  as  a  claimed 
product  has  not  been  sufficiently disclosed,  it should  not  be  considered 
unpatentable  simply  because it was  part  of  a  pre-existing natural  material. 
Although  an  invention  may  involve  a  naturally occurring  substance,  such  as  an 
alkaloid  isolated  from  a  plant  root,  or  a  biological  factor  isolated from  an 
animal  organ,  there  will  be  a  considerable  difference  between  the  product  as 
it existed  in  nature  and  the  product  in  a  useful  form.  As  such  it  is different 
from  the  product  as  it existed  in  nature.  The  so-called natural  material  has 
been  changed  by  human  intervention and  the  form  in which  it is  claimed  for 
patent  purposes  is  not  the  same  as  that  in  which  it· exists  in  nature.  Such 
products  must  in  any  event  comply  with  all  the  criteria of patentability 
<novelty,  inventive  step and  industrial applicability). 
The  EPO  Examination  Guidelines  also  recognise this  rule.  There,  it is said 
that  if a  substance  found  in nature  must  first  be  isolated  from  its 
surroundings  and  a  process  for  obtaining it is developed,  such  process  is 
patentable.  Moreover,  if the  substance  can  be  properly  characterised either  by 
its structure,  by  the  process  by  which  it is obtained or by  any  other 
parameters,  and  it is "new"  in the  sense  of  having  no  previously  recognised 
existence,  then  the  substance per  se  may  be  patentable  (C-IV,  2.3)  unless  it 
is specifically excluded,  such  as  plant  or  animal  varieties. 
This  Article  is different  from  Article  2  which  addresses  the question of  the 
patentabililty of  living matter  as  such,  whether  microorganisms,  plants  or 
animals.  Here,  the  products  are  likely to be  other than  living organisms 
themselves,  for  example,  plasmids,  DNA  (deoxyribonucleic  acid)  segments, 
proteins,  peptides,  enzymes  and  the  like. - 43  -
Article  9 
A basic  principle of  patent  Law  is  that  a  mere  discovery  is unpatentable.  A 
discovery  is defined  in the  Geneva  "Treaty on  the  International 
Recognition  of  Scientific  Discoveries"  of  1978  as  the  recognition  of 
phenomena,  properties or  laws  of the material  universe.  Objections  to 
patentability of  natural  substances  - living or non  -may be  raised  on  the 
basis  that  such  products  are discoveries  and  therefore that  they are  not 
''new".  Such  objections  are  usually  raised  in  the  biotechnological  context,  as 
noted  above,  for  the  sole  reason that  the  products  were  present  in  a 
pre-existing material  which  itself may  or  may  not  be  part  of  the  prior art  for 
patent  Law  purposes.  Article  9  deals  with  the  two  related  issues  of discovery 
and  lack of novelty. 
According  to  the  EPO  Examination  Guidelines,  if a  new  property  of  a  known 
material  or  article is discerned,  it would  constitute a  discovery  and  would  be 
unpatentable.  If,  however,  the  new  property  is put  to practical  use,  the 
result  may  be  a  patentable  invention.  If a  natural  substance  is sought  to be 
patented,  the  Guidelines  note  that the  line of  demarcation  between  the  mere 
discovery  of  a  natural  substance  and  its patentability will  depend  on  the 
degree  of  human  technical  intervention necessary  to obtain it  (C-IV,  2.3). 
~Jhere  a  substance  is  claimed  in a  form  which  results from  human  intervention 
in  the material  world,  it is more  than  mere  discovery,  irrespective of  whether 
the  intervention  is  simple  or  complex.  Article 9  is necessary to ensure that 
this distinction is  correctly applied  in patent  law.  As  to the  argument  that 
such  products  are not  "new",  a  product  is  considered "new"  under  the patent 
Laws  of  most  Member  States  if it does  not  from  part of  the  "state of  the  art". 
The  state of  the  art  is deemed  to be  everything  which  has  been  made  available 
to the  public  by  means  of  a  written or oral  disclosure,  by  use  or  in  any  other 
way  before  the  patent  application was  filed  (for example,  Article  54  EPC).  The 
fact  that  a  product  may  have  existed  in  a  mixture  before  its identification, 
isolation,  purification and  usefulness  have  been  established does  not  render 
it part  of  the  state of  the art  for  purposes  of  patent  Law  because  it was 
effectively  "not  available"  to the public  by  any  means. - 44  -
The  principle  required  by  Articlo  9  doc&  not  prejudge  th~  1~nuc of  the  nov~Lty 
of  the  product.  If  information  was  available as  to the existence of  the 
particular mixture  in question,  and  if the  information  available  could  have 
made  the particular product  foreseeable  as  a  separate entity and  would  have 
enabled  the  person  skilled  in  the art  to  render  it  into useful  form,  such 
product  may  be  considered  not  to be  new.  In  the absence  of specific 
information,  and  if a  product  isolated  from  a  mixture  or  synthesised  is 
physically different  from  the mixture  which  was  available to the public  prior 
to the  invention,  novelty  should  be  admitted  as  a  matter  of  principle. 
Article  9  will  ensure that  an  invention  is not  erroneously  considered 
unpatentable  as  a  discovery  simply  because it was  once  part  of  a  pre-existing 
mixture. - 45  -
CHAPTER  2 
Scope  of Protection 
Article 10 
Article  10  is addressed  to the  issue of  experimental  use  of  a  patented 
invention  involving  living or self-replicable matter.  The  issue of 
experimental  use  in  patent  Law  is not  dealt  with  in the  EPC.  Article  31(b)  of 
the 
11Convention  on  the  European  Patent  for  the  Common  Market"  (CPC)  states 
only that the  rights  conferred  by  a  Community  patent  shall not  extend  to: 
acts  done  for  experimental purposes  relating to the  subject-matter 
of  the  invention. 
Under  national  patent  laws  as  well,  experimental  use  of  a  patented  invention 
does  not  consitute  patent  infringement  but  interpretations vary  of what  acts 
constitute experimental  use. 
If a  patented biotechnological  product  is employed  to produce  an  improvement 
over  the  previous  product,  such  use  may  Legitimately  be  regarded  as 
experimental  usc.  If  the  improved  product  is  a  biotechnological  product  which 
is self-replicating,  the  patented starting material  need  only  be  prepared once 
in  small  quantities.  To  obtain  commercial  amounts  it would  not  be  necessary 
to  reuse  the  product  enjoying  patent  protection or to find  a  new  way  of 
production,  avoiding  the direct  use  of  the  patented product,  as  would  be  the 
case,  for  example,  with  a  patented chemical  product  unable  to  reproduce 
itself.  Replication of  the  small  amount  cibtained  in  the first 
11experiment" 
with  self  reproducing  material  would  suffice. 
In order to safeguard  the patent  rights granted  for  the first  invention  and 
thereby  place  the  inventor  in  such  a  case on  an  equal  footing  with  inventors 
in other fields,  Article  10  is necessary  to qualify  the first  use  of  the 
patented  product  to obtain even  a  small  amount  of  a  new  or  improved  product  as - 46  -
experimental  use  so  long  as  the  improved  product  is  multiplied  for  other 
experimental  purposes.  If multiplication were  for  commercial  purposes,  then 
such  use  of  the  new  product  would  not  be  covered  by  the  patent  law  doctrine  of 
experimental  use. 
It would  be  irrelevant  whether  an  improved  product  is obtained  from  a  product 
enjoying  patent  protection  in one  or  several  process  steps.  What  is essential 
is  whether  any  new  product  obtained  by  using  a  patented  product  is 
manufactured  by  multiplication of  the material  obtained  from  the  patented 
product.  Article  10  establishes  the  minimum  necessary  point  beyond  which  the 
use  of  patented  self-reproducing products  will  not  be  considered  experimental, 
that  is, at  commercialisation. 
Article  10  is needed  in  part  because of  the  variety of  interpretations  of  what 
acts  constitute experimental  use.  Hore  importantly,  it establishes  a  rule for 
patented  living matter  consistent  with  patent  law  doctrine  applicable  in  other 
fields  of  patentable subject  matter. 
Article  11 
Under  traditional  patent  law  doctrine,  the  purchaser  of  a  patented  product  may 
use  such  product  in  any  manner  he  deems  fit.  A purchaser  may  put  the  product 
to  such  use  as  is  consistent  with  its purchase,  for  example,  a  patented 
machine  may  become  part  of  a  factory  production  process;  a  patented  chemical 
may  be  used  to treat  plants  or  kill  insects,  etc. 
It  is  a  well-established patent  law  principle that  a  purchaser of  a  patented 
product  is not  allowed,  unless  it has  been  specifically agreed,  to manufacture 
the  patented product  itself.  The  jurisprudence of  the  Court  of Justice has 
recognised  the patentee's  right  "to use  the  invention  with  a  view  to 
manufacturing  industrial  products and  putting them  into circulation for  the 
first  time"  (Centrafarm  B.V.  et al.  v.  Sterling  Drug  Inc.  1974  ECR  1147  at 
1162). 
The  Treaty's articles on  the  free  movement  of  goods  should  not  be  confused 
with  the  patentee's exclusive  rights to produce  patented products.  The 
principle  in the  Treaty  of  Rome  in  respect  of  the  free  movement  of  goods - 47  -
<Articles  30  to 36)  has  also  resulted  in  the  development  of  an  exhaustion 
principle  as  applied  to  trade  between  Member  States  including  goods  covered  by 
industrial  property.  Once  a  patented product  has  been  placed on  the market  by 
a  patentee  or  with  his  consent,  no  control  over  the  further  use  of  the product 
in  intra-Community  trade  may  be  exerted  by  the  patentee  or  a  licensee. 
The  exhaustion  of  rights  which  applies  under  the  Court's  interpretation of 
these  articles  relates  to three activities:  the  use,  offer for  sale  and  sale 
of  a  product  covered  by  industrial property  rights.  Use  in such  a  case 
relates  to  use  of  the  product  in  commerce  in  intra-Community  trade.  It does 
not  include  the  manufacture  of  products  covered  by  industrial property  rights. 
Patent  rights  would  not  be  exhausted  for  the  production of  the  patented 
product  until  the  patent  term  itself expired. 
The  purpose  of  Article  11  is to establish this  rule  for  patented  living or 
self-replicable matter.  Thus,  the purchaser of,  for  example,  patented barley 
may  use  his barley  to  make  whisky  without  infringing  the  patent;  the  purchaser 
of  patented  malt  or  yeast,  for  example,  may  use  these products  to make  beer 
without  infringing  the  patent.  Both  uses  involve  a  certain amount  of 
multiplication  <such  as  germination)  of the  product  sold but  such  uses  are 
clearly  intended  by  the sale. 
Where  patented self-replicating material  is  sold  for  purposes  of  propagation, 
for  example,  seeds,  the  purchaser  usually  a  farmer  will  have  the  right  \lithout 
patent  infringement  to  use  the  products  for  the purpose  for  which  he  purchased 
such  seeds,  i.e.  to grow  a  crop  for  harvesting  even  though  such  use 
unavoidably  involves  multiplication of  his  seeds.  The  patent  rights  would 
not  be  exhausted  in  respect  of  the  use  of  the  crop  grown  from  the  patented 
seeds  as  a  source  for  the  sale  of  new  propagating material  <seeds)  as  this 
would  involve  production  for  the  purposes  of  selling the patented product 
itself.  <Any  variety  rights  inherent  in  seeds  protected  by  plant  breeders' 
rights  would  similarly be  unexhausted  in  respect  of  the use of  the  crop grown 
from  the  seeds  as  a  source  for  the  sale of  new  propagating material). 
Article  11  will  ensure  that  the  use  which  is  intended  in  a  sale of  patented 
self-reproducing material  is  not  confused  with  a  use  which  involves  patent 
infringement.  The  provisions of Article  11  are needed  because  the  issue of - 48  -
the extent  of  patent  rights  in  respect  of  patented  living or  self-replicating 
material  has  not  been  dealt  with  in any  national  patent  system  and  the 
provisions  of  the  EPC  do  not  address  this question,  save  that  the  rights 
conferred  by  a  European  patent  are  said to be  the  same  as  would  be  conferred 
by  a  national  patent  (Article  64(1)  EPC).  Infringement  of  European  patents  is 
considered  under  national  law  principles taking  account  of  EPC  requirements 
regarding  claim  interpretation.  The  issue  which  is  addressed  in  Article  11 
therefore  is not  regulated  by  any  specific provision of  the  EPC. 
The  CPC,  of  which  seven  out  of  the nine  original  signatories  have  adopted  laws 
ratifying this  Convention,  at Article 32,  provides  that  the  rights  conferred 
by  a  Community  patent  shall  not  extend  to  acts  concerning  a  patented  product 
within  the  territories of  the  contracting States after the  product  has  been 
put  on  the  market  in  any  State  by  or  with  the  consent  of  the  proprietor of  the 
patent  unless  there  are  grounds  under  Community  Law  which  would  justify the 
extension of  the  patent  rights  to  such  acts.  Article  81  of  the  CPC  provides 
the  same  principle  in  respect  of  national  patents. 
The  intention of  the drafters  of  these  provisons  was  to  incorporate  into the 
provisions  of  the  CPC  the  prior and  future  jurisprudence of the  Court  of 
Justice dealing  with  the  interpretation of  Articles  30  and  36  of  the  Treaty  of 
Rome.  These  provisions,  as  has  been  demonstrated  above,  relate to different 
principles  of  Community  law  than  those dealt  with  in  Article  11  of  the 
Directive. 
Article  11  is necessary  therefore  to distinguish  between  the  meaning  of  "use" 
for  different  purposes  of  national  patent  Law,  the  EPC  and  the  CPC.  For 
national  patent  laws,  it needs  to  be  legislatively established that  use  which 
involves  propagation solely for  the purpose  of  obtaining additional 
propagative  or  self-replicating material  does  not  come  within  the  scope  of 
intended  use  which  would  be  exhausted  upon  the  sale of  a  patented product. 
The  patent  rights  inherent  in  the  use  of material  such  as  seeds  are  not 
exhausted  for  a  use  which  consists of  multiplying  such  material  solely  to 
obtain  more  thereof.  Without  Article  11,  the  relationship of  the  exhaustion 
principle under  Articles  30  to  36  of  the  Treaty of  Rome  and  exhaustion  of 
patent  rights  for  self-replicating material  under  national  patent  Laws  might 
have  remained  unclear. - 49  -
Article  12 
In  traditional  patent  law  doctrine,  the  protection  conferred  by  a  patented 
process  extends  to the  product  produced  by  the  protected process.  This 
principle exists  in  the  laws  of most  Member  States  and  is also  found  in  the 
EPC  (Article 64(2)). 
Where  a  patented  invention  is  a  process  which  makes  use  of  living  or 
self-replicable matter,  the  scope  of  the  patent  rights conferred must  be 
ascertainable.  Putting  things differently,  both  a  patentee  and  third parties 
must  be  apprised  of  the  point  at  which  patents  rights  in  such  material  are 
exhausted.  Article  12  addresses  this  issue. 
The  product  obtained  from  the  patented process  may  be  either  living matter  or 
other matter  which  is  capable  of  self-replication,  for  example,  a 
microorganism  which  can  be  cloned  or  a  plant  cell  which  can  be  differentiated 
to yield the  plant  itself.  It will  readily  be  recognised  that  matter  which  is 
capable  of  reproducing  itself may  be  purchased  in  small  quantities and 
subsequently  made  to  reproduce  under  appropriate  conditions.  The  effect  of 
the  patent  rights  conferred  by  the  process  would  be  completely nullified if 
further  generations  of  the  microorganism  or differentiated plants  would  no 
longer  benefit  from  the  patent  protection  accorded  to the process. 
Two  specific sitations  in  which  a  need  for  the  principle of  Article  12  may  be 
envisaged are: 
(1)  where  a  patented process  is carried out  in  a  country  where  no  patent 
protection exists  and  either the first generation of  said product  but, 
more  usually,  a  second  - usually multiplied - generation  is  imported  into 
j 
a  country  where  patent  protection has  been  accorded;  and 
<2)  where  the direct  product  of  the  process  is,  for  example,  a  seed  or  a 
cell  which  can  be  regenerated  to a  plant,  the  se~d or the cell  is 
produced  in  a  country  where  no  patent  protection exists  and  the  plant  or 
plant  material  produced  therefrom  is  imported  into  a  country  where  patent 
protection does  exist. - 50  -
rrti~lc 12(1)  ~ill  therefore  estnbl1~h that  potent  protection  ~ill  ext~~d not 
c~ly to  tl1osc  produr1~  initi~lly cht~ined  f~om the  precEss  but  al~n tn further 
1u::~~r  genrr~tion~ of  microorgnnigm~ Or  regen!rat~d plants  ~re rroductS  Wh0SC 
prOf.lt'i'ties  uhich  were  iPitially obtained  by  the  process  art- :titl presr-nt  and 
arc  determinative  of  their value.  Such  prod~cts should properly  be  regarded  as 
''direct"  products  o~  pDt~nted processes.  Thus  plants  would  benefi~ from  t~c 
orotection of  the  direct  product  of  a  process  for  the production of  a  plant 
cell or  parts  of  plants  when  regenerated  from  su~h  cell~ or parts. 
There  may  also be  cases  where  the product  of  a  protected  procc!:~'  :ake~:  the 
form  of  a  variety.  Article  12(2)  is necessary  to  ensure  thai  protection  is 
nonethele~s accorded,  even  where  the  patented  pro~ess produces  plant 
var·ieties.  Although  varieties arc  excluded  in  most  national  patent  la:!s  as 
such  from  patent  protection,  they  are not  excluded  from  protectior:  as  products 
of  patented processes. 
This  view  is  found  in  the  Report  on  the  1975  Luxembourg  Conference  on  the 
Community  Patent  Convention  CCPC),  1981,31 •  During  the  discussion  of  Articl~ 
29Cc)  CPC,  it was  questioned  whether  it would  be  possible to protect  2  plant 
variety or  animal  variety  by  means  of  the  principle  in Article  29,  th~t  is,  as 
a  "direct  product"  of  the  patented  process.  It  was  agreed  ~Y  the  ronference  tu 
revise  Article  29Cc)  following  the  int~rventions of  two  Member  States  to  the 
effect  that  protection of  plant  and  animal  varieties  as  direct  p;·cdiJCt:s  of 
patented  processes  was  not  excluded  even  though  varieties were  excl!Jded  per  se 
in the  EPC  <Article  53Cb)  EPC).  This  was  felt  to  result  from  tile  patent  law 
principle that  the  protection conferred  by  a  patented process  extends  to  the 
products directly obtained  by  such  process  <Article  64(2)  EPC). 
The  European  Patent  Office  (EPO)  has  not  yet  adopted  a  definitive position  on 
this  issue.  The  Commission  agrees  with  the  views  of  the  govern~entnl 
Conference  and  has  therefore proposed the  same  rule  in  Article  12(2)  in 
respect  of  n~tional patent  Laws.  Article  12(2)  will  therefore  legislatively 
------------------------
31t~inutes of  the  Conference  published  in  Records  of  the  Luxembourg  Conference 
on  the  Community  Patent,  1975,  Luxembourg  1981,  footnote  75,  p.234. - 51  -
establish the principle  for  national  patent  laws  that  the  protection of  a 
patented process  Yilt  extend to the products of  such  processes,  even  where 
these  include  plant  and  animal  varieties. 
Since  national  patent  laws  contain the  same  wording  as  the  CPC  in this  regard, 
it is envisaged that  adoption  of  this principle for  national  patent  systems 
will  result  in  a  greater degree of  harmonisation between  the  EPC  and  the  CPC 
on  the one  hand  and  the  national  patent  systems  on  the other. 
Article  13 
As  a  result  of  the  Directive greater possibilities will exist  for  patenting 
products  consisting of  or  containing genetic  information,  such  as  a  particular 
DNA  segment~  Where  such  biological products  are  incorporated  into  a  more 
complex  product,  such  as  where  the  DNA  is  incroporated  into a  host 
microorganism  which  may  be  multiplied,  the  patent  protection enjoyed  by  such 
products  should extend  to all products  in  which  the particular genetic 
information  which  was  essential  for  the  invention  remains  of  essential 
importance  for  the  products  concerned. 
Where  the  patented material  is  incorporated  into a  plant  or  animal  variety, 
such  variety may  Legitimately  be  subject  to the  rights granted  in  the patent. 
Article  13  will establish this principle  for  national  patent  rights.  Two 
arguments  have  been  advanced  to suggest  that  this  result  would  be 
inappropriate:  first,  because  manufacturing  steps  were  required  to obtain  the 
variety  from  the  patented product;  and  secondly,  because plant  varieties  are 
excluded  from  patentability. 
A~ to the first  argument,  if the particular  industrial applicability or 
usefulness  of  a  variety directly results  from  an  invention which  has  been 
patented,  then  such  a  variety owes  its unique  characteristics to  the  effects 
of  the  invention  and  should  therefore  come  within  the  scope  of  protection 
accorded  by  the patent.  Where  an  invention  is of  no  commercial  importance  for 
the variety,  then  a  different  issue  uould  be  raised.  This  situation is not 
addressed  in the  Directive  because  Article  13  specifically stipulates that  the 
patented  invention rnust  be  of  essential  importance  for  the utility or 
indu~trial applicability of  the  final  product. - 52  -
t::.  tc  ':he:  SP.cor.:i  argu,:Jcnt ..  i'ln  exclus·ion  of  var~cties fro':l  pater.~~bilit;;  ~s  11nt 
~;'rwnycous  1d!f,  b::i.~,:.  frt:~:  fror.  t:Jf'  scope r/?  rcl~~v.J;lt  p:'1te:1t.  In  future 
t~ ·rc  2.re  t  ikE:~y  ':')  br.;  liiVN~ti(JoS  rll;":ible  .)f  ;.ppl)r.;::ltion  in  ,,,an}·  ·.~itf,n., ,t 
pl<.":-,t  v.:o:,J'ieti·~".  i-Or  exm.1plc,  reristDnCC  tO  diSCC!SE:  Oi  h~:rbicid'!  t:·~f:r'i'lfiCt'  :nr~y 
Lc  g,~net ic;.t Ly  incorporated  into  a  broad  range  of plants  COII<}t';il:J  ,·nan/ 
d~  fercnt  varictic~.  Thus,  to  be  excluded  from  patentability does  not  mean 
thnt  ~  variety  shou!d  b~ free  from  the  effects of  a  patent  gr~ntcd in  a  cdse 
where  Jn  invention  in  the  field of  pl~nts concerns  a  generic  r.cncept  which  is 
ci1:r~cterised by  new  generic  information  and  which  can  be  realised  in  a 
multitude  of  different varieties. 
Article  13  is necessary  so  that  this  important  principle of  ~atent  low  is 
explicitly  recognised  for  inventions  which  do  not  parmit  their direct 
exploitation but  which  must  become  part  of  another entity  in  urdr.r  to  be  used 
effectively.  It  would  be  an  insufficient  incentive  for  ensuring  thcit  necess~ry 
research  is undertaken  to  accord  patent  protection only  to  mote~i~l  whic:1  ~n 
its own  has  no  commercial  value.  Patent  rights  must  be  legisl~tivcly 
prescribed for  any  final  product whose  utility,  commercial  value  or  industrial 
~pplicability depends  on  a  patented  invention.  The  rule must  bl  Lcgisl~tively 
mandated  in  light  of  the  variety of  views  on  thi:  issue  for  which  AXi~~ing 
patent  laws  provide  no  solution.  Without  Article  13,  it might  be  considered 
that  the  patent  protection of  a  biological  product  uould  be  lost  if  su~l, 
product  becomes  part  of  a  more  complex  final  product  even  though  su~h 
biological  product  is  of  essential  importance  for  commercialising  Lhe  final 
product. 
CUAPTER  3 
Dependency  License  for  Plant  and  Anioal  Varieties 
Article 14 
Jt  is  foreseeable  that  if patents  are  granted to genetic  mattrinl,  to  products 
containing  such  material  ~nd to biological  classifications of  pl~nts or 
animnls  different  from  varieties,  the  situation will  arise that  new  varieties - 53  -
will  be  bred  incorporating  such  material  which  will  fall  under  the  scop~ of 
one  or  more  patents.  Commercialisation of  such  new  varieties without 
authorisation  by  the  patentee  could  constitute patent  infringement. 
The  implications  for  granting such  patents  require that  a  balancing  of 
interests be  made  as  regards  the  value  for  society of  promoting  new 
technologies  and  as  regards  the public  interest  in maintaining  a  reason~ble 
limitation on  exclusive  rights  in sensitive areas.  This  is particularly true 
in the  agricultural  sector where  the  interests of  breeders,  growers,  farmers, 
science-based  industry,  the  environment,  tax  payers  and  the  consumer  must  be 
taken  into  account. 
Article  14  is necessary  to  provide  for  the possibility  commercially  to  exploit 
new  varieties which  represent  significant technical  progress  under  a 
non-exclusive  License  as  of  right,  provided  the  patentee  enjoys  the  right  to 
receive  fair  renumeration  for  the exploitation of  his  invention.  Provision 
must  also made  for  the  patentee  to  be  granted  a  non-exclusive  royalty-paying 
License  from  the  variety  rightholder because  in  some  cases  the  inventor 
himself  may  not  be  able  to exploit  his  invention  in  a  commercially  usable  form 
unless  he  can  commercialise  the  results obtained by  his  Licensee. 
The  basic  principle  provided  for  in this article is needed  in  order  to  give 
effect  to the  public  interest  in promoting  further  developments  of 
agricultural  inventions  through  breeding activities and  to  recognise  the 
interests of  the  patentee  to enjoy his exclusive  rights  which  rights  provide 
the  incentive tor engaging  in  innovatory activities. 
The  patent  laws  of  some  Member  States already provide  for  a  dependency  or 
compulsory  license  in  the  event  that  a  subsequent  patentable  invention  cannot 
be  worked  without  infringement  of  an  earlier patent.  This  article is similar 
in that  a  variety  could  not  be  commercially  exploited  without  a  license 
granted  by  the  patentee  if  such  variety  came  within  the  scope  of  relevant 
patent  rights.  The  provisions  of  Article  14  differ  from  existing national 
patent  law  provisions  in according  a  License  of  right,  not  to a  subsequent 
patentee,  but  to a  subsequent  rightholder of  a  variety  de~eloped using  the 
patented  invention. - 54  -
There  is  no  principle of  compulsory  licensing  between  patent  and  plant  variety 
rights  which  exists  in  any  patent  or  plant  variety  law.  Article  14  is crucial 
thereforL  to  an  effective exploitation of  patented biotechnological  inventions 
in  the  plant  field.  Without  Article  14,  a  plant  variety  rightholder  would  have 
to  rely on  the  willingness  of  the patentee  to enter  into voluntary  bilateral 
agreements  for  the  use  of  the patented  invention,  which  agreements  the 
patentee otherwise  may  or  may  not  be  willing to enter  into,  on  terms  the 
breeder  may  or  may  not  be  willing  to Jgree. 
To  ben~fit from  the  provisions of  Article 14(1),  a  variety must  represent 
significant  technical  progress  compared  with  the  teaching  of  the patent.  The 
significance of  the  technical  progress  required  for  this purpose  is  a 
different  notion  from  that  of distinctness as  currently used  in plant  variety 
protection  law.  This  provision ensures  that  licenses of  right  would  only  be 
available where  the  new  variety  represents  a  genuine  agricultural  achievement 
in the first  instance,  for  example,  in successfully·introducing a  genetic 
sequence  into an  existing variety.  This  requirement  would  preclude  Licenses 
from  being  issued for  only  minor  improvements  to varieties which  had  been 
initially bred  by  incorporating  patented  inventions. 
Article  14(2)  provides that  an  application for  compulsory  licenses  may  only  be 
made  after the expiration of  a  certain period of  time.  This  period  is  a 
reasonable  measure  to ensure  that  a  patent  applicant  will  have  a  Limited 
opportunity  to make  exclusive use of or even  to  develop  for  commercial 
marketing  his  invention prior to encountering  competitors  and  competition  in 
the  market  place.  In  normal  circumstances,  competitors·would be  required to 
await  the  expiration of  the  full  patent  itself i.e.,. twenty  years  from  the 
date  of  filing of  the  patent  application,  before being  able to use  the 
invention  as  of  right  (albeit  without  the  payment  of  royalties). 
Article  14(3)  anticipates  the situation  whe~e the original  patentee  would  Like 
to exploit  his  invention  in  the  form  of  a  plant  variety  into which  it has  been 
developed  by  a  breeder.  This  provision of the  Articl~ would  accord  the 
patentee  the  right  to obtain a  non-exclusive  license  from  the breeder  to 
exploit  on  a  commercial  basis  any  variety  into which  his  invention  may  have 
been  incorporated,  upon  payment  of  reasonable  royalties.  This  provision  is - 55  -
necessary,  for  example,  to give  an  inventor  who  is not  a  breeder  the 
possibility of  commercially  exploiting his  invention  in  cas~s where  such 
exploitation may  only  be  possible  in the  form  of  a  variety. 
Article  14(4)  allocates  to a  national  tribunal  the  task  of  resolving  disputes 
between  patentees  and  holders  of  breeders'  rights  as  to the  significance of 
the  technical  progress  or  whether  the  royalties  are  reasonable.  This  is both  a 
reasonable  safeguard  and  a  necessary  measure  as  it may  be  expected  that 
disagreements  could arise over  these  issues  in  the  same  manner  as  they  may 
arise over  whether  a  plant  variety development  falls within the  claims  of  a 
patent, especially  in  the  context  of exploiting  new  and  commercially  superior 
products  in  the  plant  field.  A neutral  adjudicating body  having  the  power  to 
enforce  its  judgements  will  be  necessary for  the effective  implementation  of 
the principles  in  Article  14.  Paragraph  4  of  Article  14  is therefore 
necessary  to direct  that  the  resolution of  disputes  concerning  the application 
of  the  principles prescribed  in this article should be  determined  by  a  court 
of  competent  jurisdiction.  This  would  normally  be  a  court  seised of  a  patent 
infringement  case. 
CHAPTER  4 
Deposit,  Access  and  Re-deposit 
Article  15 
Deposit 
It  is  a  fundamental  requirement  of  all patent  Laws  that  an  enabling disclosure 
must  be  made  with  an  application for  a  patent.  ALL  Member  States  have  enacted 
a  similar  standard  in  this  regard.  An  enabling disclosure  is one  which  enables 
a  person  skilled  in  the art  to carry out  the  invention.  This  principle also 
appears  in  the  EPC  (Article 83).  It is a  requirement  whose  purpose  is 
justified by  the  grant  of  exclusive  rights  to an  inventor  in  exchange  for 
disclosure  the  invention.  This  in  turn  contributes  to technical  progress  for 
the  general  public  and  to  an  advance  in the technical  state of  the art.  Once - 56  -
the  patent  has  expired  the  enabling disclosure  provides  a  description of  how 
the  invention  may  be  reproduced  for  those  who  wish  capitalise on  the  no  longer 
patented  invention. 
In  the  c~se of  biotechnological  inventions,  the  complexity  of biological 
material  generally  makes  it  impossible  either to describe  in a  written  fashion 
the  living material  itself or  to describe  in  a  written  fashion  all  the  steps 
and  parameters  involved  to  reach  the  result  which  is sought  to be  patented.  It 
is  therefore  impossible  in  many  cases  for  the  inventor  to state  how  a  person 
skilled  in  the art  could  successfully  repeat  his  invention. 
The  unique  aspect  of  inventions  dealing  with  biological  matter  is that  they 
usually  self-reproduce themselves  under  appropriate  conditions.  In  such  a 
case,  reproduction  by  a  person  not  the  inventor of  the  steps  and  parameters 
originally employed  to develop  the  invention  ceases  to be  important  because 
the  result  desired  can  be  obtained  much  more  simply.and  reliably by 
self-replication of  the material. 
Although  the  patent  laws  require  an  enabling disclosure,  there  is  no 
legislative  requirement  that  such  disclosure  be  in written  form.  The  fact  that 
product  inventions  in traditional fields  of  technology  could  only  be  disclosed 
in the  required  manner  by  a  complete  written description of  how  to  make  the 
product  must  not  have  as  a  logical  consequence  that,  in  a  new  technological 
field,  the  legal  requirement  cannot  be  satisfied in another  manner,  namely 
through  a  reference  to a  deposit.  It is therefore  possible and  desirable,  in 
order  to  secure  the  patentability of  biotechnological  inventions which  cannot 
be  described  in  a  written  form,  to  require  that  a  system  of deposit  be 
established  for  all national  patent  systems  not  unlike that  which  already 
exists for  the  EPC.  Many  Member  States  already,  as  a  practical matter,  permit 
but  do  not  require deposit  while  at  least one  requires  that  patent 
applications  for  living matter  be  supplemented  by  reference  to a  deposited 
sample  of  the  animate  material. 
Several  Member  States  are  already parties to  the  Budapest  "Treaty  on  the 
International  Recognition of  the  Deposit  of  Microorganisms  for  the  Purposes  of 
Patent  Procedure  of  1977".  This  Treaty  establishes  accepted procedures  for 
deposits  to  be  made  for  patent  purposes.  It  regulates the technical  and  legal - 57  -
aspects  of  the  depository  institution and  of  the deposit  and  binds  the 
signatories  who  require  or  admit  such  deposits  for  patent  purposes  to accept, 
for  purposes  of  their  national  patent  procedure,  a  deposit  made  in  accordnnce 
with  the  Treaty  in  any  depository  institution provided  by  the  Treaty.  This 
Treaty  does  not  oblige  the  signatories  to  accept  a  deposit  for  purposes  of 
national  patent  law  procedures. 
Article  15  of  the  Directive  requires  the principle to  be  adopted  that  the 
deposit  mechanism  will  be  recognised  in all national  examining  offices  for 
patent  application purposes  both  for  process  and  product  patents.  Such  a 
principle  is  necessary  in  light  of  the differences  in national  practices  and 
requirements.  Without  the  principle that  a  deposit  may  suffice as  an  enabling 
disclosure,  the  patentability of  many  important  inventions,  for  example,  in 
the  field of  new  hybridoma  cells  for  the  production of  antibodies,  vaccines  or 
other biological  factors,  or  of  microorganisms  isolated  from  their environment 
which  may  be  valuable  agents  in the  fields  of  ecology  or agriculture or  as  a 
means  of  producing  antibiotics or biological  factors,  could be  jeopardised or 
rendered  Less  certain. 
The  EPC  regulations  have  established  rules  for  deposit  of  Living  matter  in 
connection  with  applications  for  European  patents.  The  provisions  of 
Article  15  of  the  Directive  correspond  to these  rules  <Rule  28)  for  depositing 
Living  matter  in  connection  with  European  patent  applications  with  one 
exception  and  three differences.  EPC  Rule  28  applies  to  inventions  whose 
claims  relate  to microbiological  processes or  products  thereof.  The  rule  in 
Article  15  is·not  Limited  to  inventions  involving  a  microbiological  process 
but  could  apply  to virtually any  invention which  involved  the  use  of  either a 
microorganism  or other  self-reproducing material,  which  might  be  claimed  in 
any  form  <i.e.  product,  process or  use  claims).  In practice,  the  rule of 
Article  15(1)  should  provide  a  clearer,  but  not  substantively different,  rule 
than that  found  in  Rule  28  EPC. 
Unless  such  a  clear  statement  of  the  principle of  the  extent  to  which  a 
deposit  may  complete  or  replace  a  traditional  written description of  the 
invention  is adopted  legislatively,  considerable difficulties  would  be 
encountered  in  patent  enforcement  procedures  in determining  the validity of  a 
patent,  such  as  occurred  in  the  German  Federal  Supreme  Court  decision  in  the - 58  -
''Tollwutvirus"  case  which  endorsed  a  similar deposit  rule  for  product  claims 
in Germany  but  which  had  to overrule  longstanding prior  jurisprudence to  do 
so. 
Access/Release 
The  Budapest  Treaty  does  not  regulate  the  question  of  the  release of  samples 
of  deposited material  to the public.  Issues  such  as  the  time  at  which  release 
is  required,  to  whom  and  under  what  conditions  such  release  should  take  place 
were  left  to national  and  international  Laws  - with  the  exception of  the 
minimum  requirement  that,  generally,  release  is only  made  if the  patent 
application has  been  published  <Rule  11,  Regulations  of  the  Budapest  Treaty). 
Unlike  a  traditional.  written description of  an  invention  which  always  requires 
a  third party  seeking  to work  the  invention to  invest  a  perhaps  substantial 
amount  of  time,  effort  and  expense,  access  to deposited  Living  matter  enables 
competitiors  and  would-be  users  of  the  invention to obtain  instantly and 
without  cost  the  results of  the  applicant's  research.  A single sample  may, 
under  appropriate  conditions,  be  sufficient  to begin  commercial  activities. 
In  some  cases,  a  microorganism  will  represent  an  entire factory.  Unless  the 
issues  of  the  time  and  conditions  of  release are  satisfactorily resolved, 
inventors  will  be  tempted  to  refrain  from  disclosing their  inventions  to  the 
detrimment  of  the  public  and  of  technical  progress  in this  field,  and  at 
considerable  risk  to the  inventor  whose  invention  may  be  re-invented  by 
another  or  may  Lose  its confidential nature. 
For  these  reasons  a  standardized deposit  systems  with  sufficient  safeguards 
for  the  applicant  as  to the  time  and  conditions  of  release  nreds  to be 
established  for  national  patent  Laws  so  that  equal  possibilities will  exist 
for  protecting  inventions  in this field. 
The  practice of  early publication of  a  patent  application  in  Europe  came  about 
as  a  result  of  the  introduction of deferred  examination of  such  applications 
because  most  patent  offices  had  thousands  of  pending,  unexamined,  applications 
on  file at  any  given moment.  Publication of  the  patent  application alerted 
the  public  of  the existence of  the  claims  in  pending  applications  which - 59  -
otherwise  would  have  remained  unknown  for  several  more  yenrs.  This  avoided 
duplication of  research  and  production  in  fields  covered  by  others.  The 
adoption of  a  system  of  publication and  deferred  examination  was  not  initially 
intended  to provide  industry  with  a  source  of  valuable  technical  information 
on  the  relevant  state of  the art.  Rather,  it was  more  of  a  practical 
necessity.  The  importance  and  use  of  the  publication of  patent applications 
as  a  source  of  technical,  commercial  and  industrial  information  for  interested 
circles developed  subsequently. 
Thus,  the  purpose  for  which  the  publication of  patent  applications  was  adopted 
was  to give  notice  to  the  interested public  of  areas  Likely  to be  covered  by 
future  exclusive  rights.  There  was  no  intention or  desire  to  create  the 
capability of  exploiting the  invention  for  commercial  purposes  although,  even 
with  a  written disclosure,  such  a  possibility was  not  excluded.  For  this 
reason,  a  system of  compensation  was  devised  for  the use of  an  invention prior 
to  patent  grant  following  publication. 
Since  a  written disclosure  in  a  patent  application  is open  to the  public  in 
Europe  at  the  date of  first  publication,  it has  been  argued that  the  same 
criterion should  apply  to  a  deposit  and  that  deposits  should  Likewise  be  open 
to  the  public.  This  problem  does  not  arise  in  the  USA  where  no  publication of 
the  application  is made  prior to the  grant  of  a  patent.  If a  patent  is not 
granted,  no  release  is  made  of  deposited material.  An  applicant  could  then 
make  use  of  his  invention  as  a  trade  secret.  In  Japan,  a  distinction  is  made 
between  the  initial publication of  the  application and  third party  access  to 
deposited material,  so  that  samples  are only  made  available to  the  public 
during  the  period  allocated for  the opposition procedure after the  second 
publication  indicating  the  notice of patent  grant. 
In  European  countries  with  an  early publication system,  a  rule  imposing  public 
access  rights  to deposits  from  the date of  first  publication  could  produce 
considerable  disadvantages  for  the  inventor of  a  biotechnological  invention. 
If  release  to the  public  of  deposited  material  is  made  before  patent  grant,  an 
inventor  whose  application  is  withdrawn  or  denied  would  not  have  the 
possibility of  using  his  invention  as  a  trade  secret.  Release  of  such 
material  to third parties  could  enable  them,  in  some  cases,  to begin 
commercial  activities.  While  the possibility of  losing  the  confidential - 60  -
nature  of  an  invention exists  for  all  published but  subsequently  unsuccessful 
patent  applications,  the  release of material  which  greatly facilities  the  use 
of  an  invention distorts the disclosure  rule  to the  unwarranted  advantage  of  a 
competitor because  of  the greater  immediate  value of  a  sample  of  the deposited 
material  than that  of  a  written description. 
In  respect  of deposited  animate  matter,  therefore,  it is necessary  to  separate 
the desired notice  function  of  the early publication  from  the undesirable 
effects of  providing  the  capability for  the  public  to employ  the  invention  for 
other  than  verification or  experimental  purposes.  Thus,  restrictions  and 
conditions  on  access  to  and  transmission of  any  samples  of  matter  deposited  in 
connection  with  patent  application procedures  must  be  established. 
Patent  applicants  who  have  considered making  or  have  made  deposits  in 
connection  with  their applications  have  expressed dissatisfaction with  certain 
aspects  of  the  EPC  deposit  rules  (Rule  28  EPC)  and  ~imilar provisions  of 
national  patent  systems.  Under  the  EPC  rules,  where  a  deposit  has  been  made 
pursuant  to  a  patent  application,  a  party  requesting  a  sample  must  undertake 
not  to make  it available  to third parties  and  to make  use  of  the  sample  only 
for  experimental  purposes.  These  undertakings  expire if the  patent 
application is unsuccessful,  is withdrawn  or  is deemed  to  be  withdrawn,  or  if 
the  patent  has  expired  in all designated States. 
The  undertaking  to restrict  the  use  of  samples  of  deposited  matter  to 
experimental  uses  prescribed  in  EPC  Rule  28  expires as  soon  as  the 
application is  refused  or  withdrawn  and  at  the  moment  a  patent  is granted.  In 
cases  where  the  patent  is granted,  the  patent  rights  themselves  would  prevent 
other  than  experimental  use  of  such  samples.  In  the  cases  where  no  patent  is 
granted,  ~n applicant  not  only  is obliged  to allow  samples  of  his  material  to 
be  delivered to third parties  without  any  compensation  he  also  loses  the 
confidential  nature of  his  work  and  the possibility of  exploiting  the 
invention  as  a  trade secret. 
Rule  28  EPC  was  amended  in  1979  following  wide-scale dissatisfaction with 
this  aspect  of  the  release  conditions  to  contain mainly  two  improvements: - 61  -
(1)  adoption of  the  expert  solution;  and 
(2)  an  extension of  the  undertaking  required  from  the 
requesting  party  to  include  cultures derived  from 
the  sample. 
The  expert  solution  is  an  option which  an  applicant  may  elect  which  provides 
for  release  of  a  sample  up  to the  moment  of  patent  grant  or  refusal  thereof  or 
of  withdrawal  of  the  application if a  third party  requests  a  sample  of  the 
deposit.  Release  is  made  to  an  independent  expert  ~1ho  is  himself  bound  to  use 
the  sample  only  for  experimental  purposes  and  not  to transmit  it to others 
including the  third party.  The  expert  is free,  however,  to  report  the 
results of  his  experiments  and  verification of  the  sample  to the  third party. 
The  expert  solution has  been  introduced  into the  national  patent  practices  of 
Denmark,  France  and  Italy.  The  Italian practice  is a  variant  of  the  EPC  rule 
in  that  the  expert  solution is not  optional  and  applies  for  the  entire patent 
term. 
The  expert  solution of  EPC  Rule  28  does  not  protect  the  applicant  in  a 
situation where  an  application  is withdrawn,  not  pursued  or  refused.  In 
addition,  it has  been  questioned  whether  the  rule  is  compatible  with  the 
requirement  that  an  application must  disclose  an  invention  in  a  manner 
sufficiently clear and  complete  for  it to  be  carried out  by  a  person  skilled 
in  the  art  <Article  83  EPC).  There  have  as  yet  been  no  judicial decisions  on 
this question  and  thus  on  the  issue of  the  sufficiency of  the disclosure  for 
'purposes  of  the  EPC.  Both  difficulties need  to be  addressed  in the  context  of 
national  patent  laws. 
The  obligation  for  a  patent  disclosure  to enable  the  public  to  carry  out  an 
invention  applies  to the  public  in  the  jurisdiction of  the  patent  right 
involved.  According  to the  accepted  theory  of  patent  Law,  whereby  the 
granting authority  and  the  inventor effectively enter  into a  contract  to  the 
effect  that  the  inventor  is  accorded  exclusive  rights  in  exchange  for 
disclosing  his  invention,  there  is  an  absence  of  the  quid  pro  quo  between  the 
patentee  and  the grantor  where  disclosure  in  the  form  of  a  sample  of 
self-replicating material  is provided  to the  public  of  a  jurisdiction where  no 
patent  has  been  granted  or  applied  for. - 62  -
n1•r:!  1:;  1:1  L<:g.1f  ;equircment  in patent  law  that  en  appl·icnnt  mu:>L  ~nr;u'.e  the 
::''.Jt.Li':  .  .:·  i~'···  c·:n  •. ci'it- to exploit  hi-;  ir.vc;·ytio~'  nor  ir.  :nr.:rc  f.!r;y  inrcrc.:·· 
'IIi  ti1e  p.:ort  cf  r  State  1"1'1ich  has  grantt-r.J  cxclU!:ivf>  righ:s  in  r0~p~ct of  on 
i·~·Jen\:;c-,  '!:o  r:.nke  SJ~~ples  <wc:il':lblc  to another  jurisdiction :-1here  no 
protection  e~ists.  Transmi~sion of  a  sample  of  the  deposit  to  another 
jurisdiction where  r·~~case  has  been  requested~ despite the  obs~ncc oi  rights 
&ssociated  with  ~  9atent  anolication or  ~  patent,  serves  no  gcntJinc  purpns~ of 
tl1e  patent  syste~.  Such  a  possibility should  be  minimised  fo- inventions  in 
the  field of  Living  matter. 
It hCls  t.Jeen  suggested  that  to eliminate  the possibility of  in0pur0;"·iat:e 
relet.tsc  of  samples,  the  rule  would  need  to be  adopted that  surr.p!.er,  of  the 
deposit  may  only  be  delivered  to  p~rties residing  in  a  country  for  which  or  in 
~1hich  a  patent  npplication  had  been  filed or  uhere  a  patent  hnd  bee;;  grunted. 
Such  ~n ilpproach  is unlikely  to meet  with  much  ~upport  in  Light  of  the 
well-est~blished principle of  open  disclosure  in all  p~tent  Ltw~.  A siMilar 
re~ult can  be  nchieved,  as  is· done  in Article 15(3)(b)(ii), by  imprs~ng nn 
undertaking  on  a  requesting  party that  the  sample  will  be  u~2d cnly  for 
experimental  purposes  irrespective of  the  countries  to  which  ~uch  s~m~lcs nuy 
ultimately  be  brought  or  tr<:~nsmitted.  This  restriction,  along  ~lith  l~c 
undert<:~king not  to transmit  a  sample  to  any  third partiesr  11ill  C;"~ablr·  2r1 
applic~nt  to monitor  whether  undertakings  have  been  respected  as  wc!L  as  to 
ensure  the effectiveness  of  the  undertakings  given. 
For  some  inventions,  patent  applications  will  concern  biotcchnol~~ical 
inventions  starting  from  Living  material  which  was  previously  dc~osited in 
connection uith  another  patent  application by  either the  same  or·  nnother 
person.  If  such  an  earlier deposit  had  Legnlly  become  available  to  tho  public 
not  Later  than  the  time  of  the  new  patent  application,  it would  belong  to  the 
relevant  stute of  the  art  for  all patent  Lnu  purposes.  The  pntent  lm'  concert 
of  the  state of  the  art  comprises  everything  which  has  been  mnde  uv~ilablc  in 
some  for~ to  the  public  prior.to the  filing of  a  patent  apolication.  The 
11ovelty  uf  an  invention,  as  is its inventive  step,  and  its disclosure  are 
judged  r~~i!~st  the  standard of  the  state of  the art of  the  relevant  technical 
field  cor1cerned.  If  a  microorganism  had  become  available to the  public  and 
thus  formed  part of  the  state of  the art  at  the  time  of  a  subs~quent 
applicaL~an,  there  would  ~e no  .~2ed  for  the  applicant  to  re-donosit  this - 63  -
material  or  to  maintain  such  earlier deposit.  This  result  follows  from  the 
fact  that  the  microorganism  forms  part  of  the  state of  the  art  and  would  be 
the  same  in  any  other  technical  field  for  purposes  of  patent  application 
~ 
procedures. 
Any  restriction on  the  release  of  samples  of  a  deposit  which  was  made  for 
purposes  of  patent  procedures  which  prevents  the  public  in  the  country of  the 
patent  right  from  having  access  to the deposit  after first  publication  may  put 
into question  the  loss  of  novelty  normally  accompanying  the  initial 
publication,  that  is,  it  may  be  queried  whether  or  not  such  material  is  deemed 
to be  part of  the  state of  the  art.  If  a  microorganism  or  other deposited 
animate  matter  has  become  part  of  the  state of  the art,  which  occurs  in all 
technical  fields  upon  publication of  the  patent  application,  such  matter 
should  be  regarded  as  available  to  the  public  within  the  meaning  of  novelty  or 
disclosure  for  national  patent  law  purposes.  In  consequence,  samples  could 
cease  to be  available  to  the  public  from  the  depositary  institution without 
affecting  the  novelty-destroying  or disclosure effect  of  the  published 
application.  In  as  much  as  the  public  was  provided  with  access  to the 
technical  details of  an  invention either directly or  through  an  expert  and  in 
view  of  the  fact  that  such  access  will  be  considered to constitute  an  adequate 
disclosure  of  the  invention,  it  follows  that  a  published  application  becomes 
part  of  the  prior art  independent  of  the  outcome  of  the  application.  Article 
15(10)  establishes this principle. 
Such  a  principle  needs  to  be  established particularly for  those  cases 
involving  living  or  self-reproducing matter  where  an  application does  not 
result  in the grant  of  a  patent  and  where  the  application  is  published  so  that 
one  or  more  samples  could  have  been  released either to the  public  or  to  an 
expert.  The  application of  such  a  principle  in these  cases  is analogous  to 
the situation where  a  product  has  been  exhibited  for  a  time  at  a  public  trade 
fair  and  has  consequently  become  part  of  the  state of  the art  for  all  time  and 
is thus  considered  as  being  available  to the  public.  No  obligation exists  to 
provide  another  enabling  disclosure  to the  public. 
The  system  of  early publication  and  deferred  examination  of  patent 
applications  is unlikely  to  be  changed  in  Europe  in  the  foreseeable  future. 
The  requirements  for  disclosure  of  inventions  are  closely similar  in all - 64  -
M?~ber States  both  for  European  and  national  patent  applications.  In  view  of 
the  ~10rk  nlre<~dy done  .:mci  the  consensus  already  ::;chieved  in  respect  of  EPC 
RL>.f:s  28  and  28a,  <:J;·:y  harmonisution  of  the  prov·isions  of  n<:~t ional  patl~r,t  Ln,~s 
regulcting  the  condition~ of  accEss~  release  and  re-deposit  should  pLraltcl 
f. 
those  of  the  ~rc  t~king into  account  the  shortcomings  from  which  the  EPC  rulrs 
are  thought  to  suff~r. 
Thus,  the differences  between  Article  15  of  the  Directive and  EPC  Rule  28  mJy 
be  summarised  as  follows: 
1.  The  undertaking  required  in  Article  15  paragraph 3(b)(i)  -that a  party 
requesting  a  sample  of  deposited  material  will  not  rn~ke  it available  to third 
parties- does  not  expire  while  the  undertaking  in  EPC  Rule  28  expires  if "the 
application  has  been  refused  or  withdrawn  or  is  deemed  to be  withdrawn  or,  if 
a  patent  is granted,  before  the  expiry  of  th2  patent  in the  designnt~d State 
in  which  it  last  expires"  (Rule  28(3)(a)). 
2.  The  undertaking  required  in paragraph  3Cb)(ii)  -to use  the  sample  for 
experimental  purposes  only- will  expire  only  in  those  countries  where  a 
patent  right  comes  into existence.  Once  a  patent  right  is created,  tl1c  pEtcnt 
laus  the~selvcs would  Limit  a  third party to the  use  of  a  p~tcntect  invention 
for  experimental  purposes.  This  rule  permits  those  who  have  received  s~m~l~s 
to  use  the  material  in  other  countries  for  experimental  purposes.  Under  EPC 
Rule  28,  if  a  potent  is  refused or  an  application  is withdrJwn,  tt1is 
undertaking  Hould  expire,  enabling  third parties to  commcrcialise  the 
deposited material.  This  is  an  undesirable  consequence  resulting  fro~ a 
mi~constr·ued application of  the  system  of early publication  wherein  physical 
access  to deposited  material  is equated  with  the  notice  function  of  the 
publication. 
3.  The  sample  would  no  Longer  be  available  to the  public  or  to  an  expert  if 
the  application  fails  or  otherwise does  not  Lead  to the grant  of  a  patent 
where  the  application  had  been  published  and  the deposit  was  available either 
to  the  public  or  to an  expert. - 65  -
Article  16 
Re-Deposit 
It  may  happen  that  a  depositary  institution will  no  longer  be  able  to  provide 
a  sample  of  a  valid deposit  to  a  requesting  party entitled to it for  reasons 
other  than  those  regulated  under  the  Budapest  Treaty,  for  example,  because  of 
the  dangerous  character  of  the  material  or  the end  of the  contractual  period 
of  maintenance.  It  would  be  unjust  to  refuse an  application or  to declare 
invalid  a  patent  right  on  the  basis of  such  incapacity of  the depository 
institution,  unless  the  applicant/patentee or  owner  of  the  right  could  not 
provide  the  requesting  party  with  a  sample  of  the material,  certifying  its 
identity with  the originally deposited material  <similar  to the  provisions  of 
Article  4(1)ChlC~i)  of  the  Budapest  Treaty). 
Article  16  is needed  to ensure  that  an  applicant  or  patentee  in all  national 
patent  systems  will  be  allowed  to  re-deposit  a  microorganism  or other  animate 
matter  for  patent  law  purposes  if his original  deposit  ceases  to be  available 
from  the  institution with  which  it was  deposited,  as  is provided  in  EPC  Rule 
28a  and  in similar provisions  of  some  Member  States'  laws.  The  provisions  of 
Article  10<1>  - (5)  are virtually identical  to those  of  EPC  Rule  28a  except 
that  the  D)rective  explicitly mentions  other  self-replicable matter  in 
addition  to  ~icroorganis~s. 
Situations  may  arise  where  a  re-deposit  cannot  be  effectod  by  the original 
depositor/patentee  even  Yhere  the original  deposit  has  given  rise  to the grant 
of  a  patent.  In  such  a  case,  the validity of  the  patent  may  be  questioned  as 
an  en~bling disclosure  no  longer exists  relative to the  patent.  Article  16(7) 
is necessary,  therefore,  to  ~stablish the  principle that  any  ruling  declaring 
the  invaliiity of  a  patent  on  the  basis  of  the  patentee's  inability to 
re-deposit  a  sample  of  the original material  will  not  retroactively  invalidate 
the  patent.  This  rule  is needed  because  the original grant  of  the  patent  was 
based  on  a  deposit  which  initially complied  with all the procedural 
requirement~ for  ratcnt  grant  but  which  deposit  only  subsequently  become 
unavailable  to  the  public. - 66  -
EPC  Rule  28a  does  not  address  the  question of  validity and  nullity.  It  is all 
the  more  important,  therefore,  to establish this  rule  for  national  patent  laws 
as  it will  affect  the  validity of  European  patents  in  that  questions  of 
validity not  regulated  by  provisions  of  the  EPC  are  subject  to national  patent 
law  principles  concerning validity. 
CHAPTER  5 
Reversal  of  the Burden  of  Proof 
Article  17 
After  a  patent  has  been  granted,  uncertainty  as  to  whether  the  patent  is being 
worked  on  an  unauthorised  basis  by  one  or  more  third parties  may  arise.  If  a 
patentee  decides  to  initiate  litigation in the belief  that  his  patent  claims 
are being  infringed,  he  must,  in certain situations,  bear  the  burden  of 
establishing by  a  preponderance  of  the evidence  that  infringement  has  likely 
taken  place. 
For  patents  involving  new  products,  produced  by  new  processes,  the  burden  of 
proof  that  the  patent  has  not  been  infringed  in  the  event  of dispute  usually 
rests  with  the  alleged  infringer.  This  is based  on'the premise  that  no  method 
other  than  that  revealed  in  the  patent  application is  known  to produce  the 
product  in question,  it being  non-existent  theretofore.  This  principle  has 
been  codified  into many  patent  Laws  of  the  Member  States  and  is also  found  in 
the  CPC  (Article  75). 
In  the situation where  a  patentee of  a  process  patent  suspects  patent 
infringement  is taking place,  it is often difficult to establish  whether  a 
particular product,  which  is  identical  to another  product  itself obtainable  by 
a  patented process,  has  in  fact  been  manufactured  or  produced  using  the 
patented process.  This  is particularly the  case  with  biotechnological 
inventions  where  microorganisms  may  be  used  in  patented processes  and  where 
neither  such  use  nor  the  nature  of  the  process  can  easily be  detected  in  the 
final  product. - 67  -
In  cases  where  the  product  is previously  know~ so  that  a  process  different 
from  the  one  protected  in  the  process  patent  must  have  been  available,  no 
legal  provizions  on  the  burden  of  proof  in  patent  disputes  exist  in  the  l~~s 
of  the  Member  States or  in  the  EPC  or the  CPC.  The  normal  rules of  evidence 
would  apply  to the  effect  that  the  patentee of  a  process  for  producing  a  known 
product  would  bear  the  burden  of  establishing a  prima  facie  case  by  a 
preponderance  of  the  evidence  that  infringement  of  his  process  has  probably 
occurred. 
If  a  sample  of  deposited  self-reproducing material  has  been  released,  it will 
be  difficult, if not  impossible,  for  a  patentee to prove  that  an  alleged 
infringer has  used  the  patented process  to manufacture  the  known  product,  as 
it may  al~'ays be  claimed  - without  need  of  proof  - that  the  known  unpatented 
process  was  used.  If the  burden  of  proof  remains  with  the patentee,  he  is 
unlikely  to be  able e1fectively to defend  his  patent.  If the  alleged 
infringer  is not  using  the  p~tented process,  it is' far easier for  him  to  prove 
his  non-infringement  by,  for  exa~ple, demonstrating  how  he  produced  the 
products,  than  it is  for  the patentee to prove  the  infringement. 
Thus,  in  connection  with  the  usc  of  the deposit  mechanism  to  complete  an 
enabl.ing  disclosure,  where  necessary  for  patent  application purposes,  Article 
17  is  necessary  to provide  that  the  burden  of  proof  would  be  reversed  if 
relP.asc  of  a  sample  of  deposited material  has  been  made  which  represents  a 
sufficient  mechunism  for  working  the  invention.  The  rule  of  Article  17  is 
limited  to  the  narrow  situation where  two  conditions  are  satisfied:  a 
sufficient  means  of  carrying out  the  patented  invention must  have  been 
deposited  i~  ~  cult,•re  collection and  a  sample  of  such  deposit  must  have  been 
rel~ased. 
It the  rule  were  limited  to only  those  persons  who  have  physically  received  a 
sample  from  a  depository  institution, it would  be  easy  to  circumvent  the 
reversal  in  the  burden  of  proof  by  use  of  an  intermedinry  who  requests  the 
sample  and  thereafter  transmits it to the  interested party.  Thus  the  rule 
must  be  estahli~he1i,  dnd  Article  17(1)  is necessary  in order  to establish, 
thnt  ~he  l'evers~l  of  the  burden  of  proof  is applicable  without  restriction if 
thP.  conditions  have  b~en fulfilled.  ~cnetheless, sufficient  safeguards  must 
be  provided  so  tl1at  alleg"1  ~nfringer~  ~re not  subjected to  ab~sive use  of - 68  -
this  provision  by  patentees  wishing  to  learn of  their competitors' 
manufacturing  methods.  Such  a  principle of  the  reversal  of  the  burden  of 
proof  therefore must  and  does  include  a  provision excluding  the  need  for  an 
alleged  infringer to disclose  his  confidential  business  secrets  in  adducing 
his  proof  even  if the  burden  of  proving  non-infringement  does  lie with  him. 
CHAPTER  6 
Definitions and  Final  Provisions 
Article  18 
New  production methods  in  animal  biotechnology  may  require  steps  which  might 
be  qualified as  "surgical methods".  These  include  processes  for  breeding 
cattle,  for  example,  by  estrous  synchronisation,  super-ovulation, artificial 
insemination  and  embyro  recovery  and  transfer  (a  procedure  wherein  embryos  are 
removed,  frozen  and  reimplanted  in surrogate  mothers  elsewhere)  and  processes 
for  improving  the  food  conversion  ratio  in  animals,  for  example,  by  surgical 
implantation  of  growth  stimulating or  regulating  substances. 
Most  patent  Laws  and  the  EPC  (Article  52<4>>  exclude  the  patenting of  surgical 
methods  for  treating  human  and  animal  bodies  on  the  basis that  such  methods 
are  not  industrially applicable.  For  those  methods  of  treatment  which  were 
developed  for  or  are  applied to treating and  preventing diseases or  physcial 
impairments  in  humans  and  animals,  it is usually  the  case  that  such  methods  do 
not  have  an  industrial  character,  but  possess  rather  a  medical  or  a 
therapeutic  character.  Developments  in biotechnology  have  resulted  in  Logical 
inconsistencies  not  foreseen  in the principle as  originally drafted.  A method 
of  adding  a  chemical  substance  to animal  food  to  improve  food  conversion  is 
considered  patentable  because  it is not  surgical  but  an  equivalent  surgical 
procedure  to  implant  slow-release hormones  to  improve  food  conversion  is  not 
patentable because  it  is surgical  in nature. - 69  -
It  was  not  the  intention to  exclude  from  patent  protection developments  which 
fulfil  the  criteria of  patentability if they  have  an  industrial  character.  It 
was  simply  unforese~~ that  surgical  techniques  would  be  developed  which  would 
also be  industrially applicable. 
For  biotechnological  techniques  for  animal  production  which  are of  an 
industrial or  commercial  nature  and  which  are  not  therapeutic,  such  as  those 
mentioned  above,  the  rule  should be  amended  so  that  such  methods  may  be 
patentable. if practiced for  reasons  which  are  other  than  therapeutic  and  if 
practiced on  an  animal  body.  Thus  the  rule  in this  regard  should  be  changed 
to the extent  necessary  to encourage  research  in this  field without  undoing 
the original  intention of  the drafters of  the  exclusion.  Without  Article  18, 
an  important  set  of  biotechnological  inventions  would  not  be  eligible  for 
patent  protection. 
Article 19 
The  term  "microorganism~ is used  in  two  different  ways  in the  Directive. 
First,  in  Articles  3  and  5,  this term  relates to substantive criteria for 
patentability and  establishes  rules  regarding  living matter  and  certain patent 
Law  exclusions  from  patentability.  Secondly,  in  Articles  15  and  16,  this  term 
is  used  in  relation to  procedural  requirements  regarding  disclosure  for 
purposes  of  patent  applications.  The  Directive must  avoid  limiting  the 
application of  patent  law,  both  substantively  and  procedurally,  to  only  those 
inventions  which  concern  Living  matter  Literally  coming  within the  biological 
classification of  microorganisms. 
When  the  Budapest  Treaty  on  microorganism  deposit  was  instituted  in 1977,  the 
problems  of  accepting  deposits  of  Living  matter  were  only partially 
appreciated.  In  Light  of  subsequent  developments,  this  Treaty  has  quite 
sensibly  been  interpreted to apply  to other  forms  of  Living  matter  in addition 
to microorganisms.  The  problems  which  led  to the  Budapest  Treaty  will 
continue  to be  of  importance  where  matter  is sought  to be  patented which 
contains genetic  information to  replicate or  to direct  its replication.  ALL 
such  material  shou!~ in  principle be  admitted  to the deposit  system  for 
purposes  of patent  procedure.  Thus,  any  usage  of  the  term microorganism  for - 70  -
patent  law  purpose~ must  not  be  limited  end  ~hould be  understood  to  include 
any  living matter  which  can  be  deposited  in  a  culture  collection of  the  type 
ac~nowledged by  the  Budapest  Treaty  and  its  implementing  regulations. 
The  substantive  requirements  of  patent  law  should  be  construed  in  such  a 
manner  that  Living  matter  may  always  benefit  from  patent  protection.  The 
notions  of  the  term  "invention"  should  always  be  sufficiently broad  to  include 
all new  developments  in biotechnology. 
Thus  Article  19  is needed  to establish  the  rule  that  the  term  microorganism 
should not  be  too  narrowly  construed and  that  future  developments  in 
biotechnology  in  respect  of  animate  matter  which  is  capable  of  being  deposited 
in  a  culture collection such  as  fungi,  virsuses,  mycoplasmae,  rickettsiae, 
algae,  protozoa  and  cells  can  benefit  from  the principles of  the  Directive  and 
fulfil  both  the  substantive and  procedural  requirements  of  patentability. 
This  approach·corresponds  to  the definition of  ''li~ing material"  which  was 
suggested  for  use  with  the  kinds  of material  that  should be  accepted  for 
deposit  under  the  Budapest  Treaty  (BioT/CE/II/INF/4). - 71  -
Council  Directive 
of  ••••••••••••••••• 
on  the  legal protection of  biotechnological  inventions 
( •• 1 ••• /EEC) 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to the  Treaty establishing  the  European  Economic  Community  and 
in particular Article  100A  thereof, 
Having  regard  to the  proposal  from  the  Commission, 
In  co-operation  with  the  European  Parliament, 
Having  regard  to the opinion  of  the  Economic  and  Social  Committee, 
Whereas  differences exist  in  the  legal  protection of  biotechnological 
inventions offered  by  the  Laws  and  practices  of  the  Member  States  and  such 
differences  could  create barriers to trade and  to the  creation and  proper 
functioning  of  the  internal  market; 
Whereas  such  differences  in  legal  protection  could  well  become  greater as 
Member  States adopt  new  and  different  legislation and  administrative practices 
or  as  national  jurisprudence  interpreting such  legislation and  practices 
develops differently. 
Whereas  biotechnology  and  genetic  engineering  are  playing  an  increasingly 
important  role  in  a  broad  range  of  industries and  the protection of 
biotechnological  inventions  can  be  considered of  fundamental  importance  for 
the  Community's  industrial development; 
Whereas  the  patent  system  must  adapt  to  new  technological  developments  which 
may  involve  living matter  but  which  also fulfil  the  requirements  for 
patentability; - 72  -
Whereas  no  prohibition or exclusion exists  in national  or  international  patent 
laws  which  precludes  the  patentability of  living matter  as  such; 
Whereas  national  p~tent  systems  have  in  the  past  successfully  adapted  to 
technical  developments  and  scientific breakthroughs  in according  patent 
protection to such  developments  where  appropriate; 
Whereas  the  investments  required  in  Research  and  Development  particularly  for 
genetic  engineering are  especially  high  and  especially  risky  and  the 
possibility for  recouping  that  investment  can  only effectively be  guaranteed 
through  adequate  legal  protection; 
Whereas  without  effective and  approximated  protection throughout  the  Member 
States of  the  Community,  such  investments might  well  never  be  made; 
Whereas  some  inventions  developed  through  biotechnology  and  genetic 
engineering  are  at  present  not  clearly protected  in all  Member  States  by 
existing  legislation,  administrative practice,  and  court  jurisprudence;  and 
such  protection,  where  it exists,  is not  the  same  or  has  different  attributes; 
Whereas  the  uncoordinated  development  in the  Community  of  the  legal  protection 
for  biotechnological  inventions  in  the  Mcimber  States could  result  in  the 
creation of  new  disincentives  to  trade to the detriment  of  further  industrial 
development  in  such  inventions  and  of  the  completion of  the  internal  market; 
Whereas  existing differences  having  such  effects  need  to be  removed  and  new 
ones  having  a  negative  impact  on  the  functioning  of  the  com~on market  and  the 
development  of  trade  in biotechnological goods  and  services  prevented  from 
arising; 
Whereas  international  developments  in the field of  Legal  protection of  the 
results of  biotechnology and  genetic  engineering demonstrate  the  advantages  to 
be  gained  from  approximation of  national  Legislation; - 73  -
Whereas  scientific and  technological  developments  Dre  cften o  result  of 
international  collaboration on  research  and,  in  consequence,  need  exists  to 
ensure  that  biotechnological  inventions  may  benefit  fr0.d  co~pDrablc protection 
on  an  international  level; 
Whereas  international  instruments exist or are  under  consideration  to 
harmonise  various  aspects  of  the  legal  protection of  biotechnological 
inventions,  they  are  not  sufficient  for  Community  pur~~~cs which  must  take 
account  of  the  needs  of  Community  science  and  industry  and  a  Community  market; 
Whereas  the  patent  laws  applicable at  present  in the  Member  States  contain 
disparities which  hinder  the  development of  trade  in biotechnological  goods 
and  services, distort  competition within  the  common  market  and  therefore 
directly affect  the  establishment  and  functioning  of  that  market;  whereas  it 
is particularly  important  to  remove  these disparities because  at  the  stage 
reached  at  present  in  est~blishing the  common  market,  there  would  appear  to be 
an  urgent  need  to  ensure  that  undertakings  will  be  offered the possibility of 
obtaining effective and  equivalent  legal  protection  in all  Member  States  for 
the  results of  their  research  activities  i~ any  part  of  the  Community; 
Whereas  an  approximation  of  the  legislation of  the  Member  States  is also 
nccessit~ted by  existing  language  in national  Laws  originating  in  certain 
international  patent  and  plant  variety  conventions  which  have  given  rise  to 
considerable uncertainty  as  to the possibility of  protecting biotechnological 
inventions  concer·ning  plant  matter  and  microbiological  inventions,  language 
such  as  the exclusion  from  patentability of  plant  and  animal  varieties  and  of 
es~entially biological  processes  for  the  production of plants and  animals; 
Whereas  it is necessary  to encourage potentinl  innovation  in  the  full  range  of 
human  endeavors  by  recognising  that  human  intervention t•hich  consists  of  more 
then  the  ~election of  biological material  and  allowing  such  material  to 
perform  inherently biological  functions  under  natural  conditions  should  be 
considered patentable  subject  matter  and  should  not  be  regarded essentially 
biological; - 74  -
Whereas  it is  seemly  that  the  legislation of  the  Member  States  should  be 
harmonised  in  such  a  way  so  as  not  to conflict  with  the existing  international 
conventions  on  which  many  Member  States'  patent  and  plant  variety  laws  are 
based; 
Whereas  the  Community's  legal  framework  on  the  protection of  biotechnological 
inventions  can  be  limited  to  laying  down  certain principles as  they  apply  to 
the  patentability of  living matter  as  such;  to  the ability to  use  a  deposit 
mechanism  ~n lieu  of  written descriptions  to satisfy the enabling disclosure 
requirements  for  patent  application  procedures;  to  a  reversal  of  the  burden  of 
proof  where  release  of  self-replicable matter  has  occurred and  to  the  right  to 
a  non-exclusive  dependency  license for  plant  and  animal  varieties; 
Whereas,  in  view  of  the  fact  that  the  function  of  a  patent  is to  reward  the 
inventor  with  an  exclusive  but  time  bound  right  for  his  creative efforts and 
thereby  encourage  inventive activities, the  rightholder should  be  entitled to 
prohibit  the  use  of  patented self-replicable material  in situations analogous 
to  those  where  it would  be  permitted to prohibit  such  use  of  patented, 
non-self-replicable products,i.e.  in  respect  of  the production  of  the  patented 
product  itself; 
Whereas,  in  the  area  of  agricultural exploitation of  new  plant  characteristics 
resulting  from  genetic  engineering,  guaranteed  remunerated  access  in the  form 
of  licenses  of  right  must  be  provided  for  as  an  exception to the general 
principles of  patent  law, 
HAS  ADOPTED  THIS  DIRECTIVE: 
CHAPTER  1 
Patentability of  Living  Matter 
Article  1 
Member  States shall  ensure  that their national  patent  laws  comply  with  the 
provisions of this  Directive. - 75  -
Article  2 
A subject  matter of  an  invention shall  not  be  considered unpatentable  tor  the 
reason only  that  it  is  composed  of  living matter. 
Article  3 
1.  Micro-organisms,  biological  classifications other  than plant  or  animal 
varieties as  well  as  parts of  plant  and  animal  varieties other than 
propagating  material  thereof  of  the  kind  protectable under  plant  variety 
protection  law  shall  be  considered patentable  subject matter.  Claims  for 
classific~tions higher  than varieties shall  not  be  affected  by  any  rights 
granted  in  respect  of  plant  and  animal  varieties. 
2.  Notwithstanding  the  provisions  of  paragraph  1,  plants  and  plant  material 
shall  be  considered patentable subject  matter  unless  such  material  is 
produced  by  the  non-patentable  use  of  a  previously  known  biotechnological 
process. 
Article  4 
Uses  of  plant  or  animal  varieties and  processes  for  the  production thereof 
shalt  be  considered  patentable  subject  matter. 
Article  5 
Microbiological  processes  shall  be  considered  patentable  subject  matter.  For 
purposes  of  this directive,  this term shall  be  taken to mean  and  to  include a 
process  <or  processes)  carried out  with  the  use  of  or  performed  upon  or 
resulting  in a  mirco-organism. 
Article 6 
A process  consisting of  3  succession  of  steps shall be  regarded a 
microbiological process,  if the  essence of  the  invention  is  incorporated  in 
one  or  more  microbiolooical  steps of the process. - 76  - . 
Article  7 
A process  in  which  human  intervention  consists  in more  than selecting  an 
available biological material  and  letting it perform  an  inherent  biological 
function  under  natural  conditions  shall  be  considered patentable subject 
matter. 
Article  8 
A subject  matter  of  an  invention,  including a  mixture,  which  formed  an 
unseparated part  of  a  pre-existing material,  shall  not  be  consider·ed 
unpatentable  for  the  reason only that  it  formed  part  of  said natural  material. 
Article 9 
A subject  matter  of  an  invention,  including  a  mixture,  which  formed  an 
unseparated  part  of  a  pre-existing material,  shall  not  be  considered  as  an 
unpatentable discovery or as  lacking novelty  for  the  reason only that  it 
formed  part  of  said natural  material. 
CHAPTER  2 
Scope  of Protection 
Article  10 
The  use  of  a  product  protected by  a  patent  comprising or  consisting of genetic 
information  to develop  another such  product  or the use of a  patented process 
to obtain such  a  product  shall not  be  regarded  experimental  for  purposes  of 
establishing patent  infringement,  if the developed  product  obtained  from  the 
experiments  or  its progeny  in identical or differentiated  form,  is  used  for 
other  than  private or experimental  purposes. - 77  -
Article  11 
If  a  product  enjoying  patent  protection and  put  on  the  market  by  the  patentee 
or  with  his  consent  is  self-replicable, the  rights  conferred  by  the  national 
patent  shatt  not  extend  to  acts of  multiplication and  propagation only  where 
such  acts  are  unavoidable  for  commercial  uses  other than multiplication  and 
propagation. 
Article  12 
1.  If  the  subject  matter  of  a  patent  is a  process  for  the production  of 
living matter  or  other  matter  containing genetic  information permitting its 
multiplication  in  identical  or differentiated  form,  the  rights  conferred by 
the  patent  shall  not  only  extend to the  product  initially obtained  by  the 
patented  process  but  also  to the  identical or differentiated products  of  the 
first or  subsequent  generations obtained  therefrom,  said products  being  deemed 
also directly obtained  by  the  patented process. 
2.  Any  extension  of  the  protection conferred  by  the  patent  to  a  process  as 
indicated  under  paragraph  1  to  a  product  obtained  thereby  shall  not  be 
affected by  any  exclusion of  plant or animal  varieties  from  patentability. 
Article  13 
The  protection  for  a  product  consisting of  or  containing particular genetic 
information  as  an  essential characteristic of  the  invention shall  extend  to 
any  products  in  which  said genetic  information  has  been  incorporated  and  is of 
essential  importance  for  its industrial applicability or utility. ...  ·; g  .. 
Art ict-::  '14 
1.  If  the  holder  of  a  plant  breeders'  right  or  a  variety  c~~tificatP.  can 
e~ploit or exercise  his  exclusive  rignts  only  by  infringe~ent of  the  riql,ts 
attach~cl to  a  prior  national  patent,  a  non-crclusive  licensr  0:  r1ght  ~ho!L  bP 
<Jr.corded  to  the  breeders'  right  holder  to  the  cxt.•r1t  r~cr2ssar_i  fer  c:1e 
2xploi  ~e~t 1cn  of  such  breeders'  rinht  \!her~  IJ,.;;  v.1r  iety protected  . eprc·~cnts  :;, 
significant  technical  progress,  upon  payment  of  reasonable  royalties  h~ving 
regard  to  the  nature  of  the  patented  invention  and  consistcn~  ui:~ giving  the 
propri(;'to~ of  such  pater.t  due  reward  for  the  investment  lead~n(1  ~:'  ;;mr; 
developing  the  invention. 
2.  A license  under  paragraph  1  shall  not  be  available  prior  t~ tl1e  expiration 
of  three  years  from  the  d~te of  the  grant  of  the  patent  or  four  years  from  th2 
date  on  whicf1  the  application  for  a  patent  was  filed,  whichever  ~~riod  Last 
expires. 
3.  If  v  l·icense  according  to  paragraph  1  hns  been  gr·antf:d,  <:~nd  if" ·u~rH·•·i' 
protected  by  a  plant  breeders'  right  or  variety certificate  ~an h.  0x~lc:~(~ 
by  the  f.iatentec  only  by  infringemt:nt  of  the  rinhts  attached  to  such  var~cty.  -
non-excltJ~ive  license  sh~ll be  accorded  to the original  ~0lrnte0 :o tht  rxtent 
necessary  for  the  exploitation of  the  breeders'  right  or  variety  ~0rtificJt~, 
upcn  payment  of  reasonable  royalties  having  regard  to the  nature  of  the 
improvem~nt  and  consistent  with  giving  the  proprietor  of  the  brr~ders'  right 
due  re"<Jaru  for  the  investment  leading  to  and  developin9  the  rieH  :i;·1ety. 
:+.  t'7;.-r::  c.iizagrcements  arise  with  regard  to  the  significance of  the  ttchn.;cal 
1)r  ~.,. e:ss  and  ns  to  the  Level  of  royt:llties,  t•lember  Statez  s:,1ll  prdvid~ for  a 
court  of  competent  jurisdiction to  resolve  the dispute. - 79  -
CHAPTER  4 
Deposit,  Access  and  Re-Deposit 
Article  15 
1.  If  an  invention  involves  the  use  of  a  micro-organism or other 
self-replicable matter  which  is not  available to the public  and  which  cannot 
be  described  in  a  patent  application  in  such  a  manner  as  to enable  the 
invention  to  be  carried out  by  a  person  skilled  in  the art, or  if it  concerns 
such  matter  per  se,  the  invention shall only  be  regarded  as  being  disclosed 
for  purposes  of  national  patent  law  if: 
(a)  the  micro-organism  or other  self-replicable matter  has  been  deposited 
with  a  recognised depositary  institution not  later than  the  date  of 
filing  of  the application; 
(b)  the  application as  filed  gives  such  relevant  information  as  is 
available  to  the  applicant  on  the characteristics of  the 
micro-organism  or other self-replicable matter; 
(c)  the depositary  institution and  the file  number  of  the deposit  are 
stated  in  the  application. 
2.  The  information  referred to  in paragraph  1(c)  may  be  submitted: 
(a)  within  a  period of  sixteen months  after the date of  filing  of  the 
·application or,  if priority is  claimed,  after the priority date; 
(b)  up  to the date  of  submission of  a  request  for  early publication of  the 
application; - 8G  -
(c)  with~~ one  month  after  the  national  patent  office  has  comm1Jnicated  to 
the  applicant  that  a  right  to  inspection of  tt1e  filPs  ~~ists pursuant 
to  paragraph  3Ca)Cii)  below. 
The  ruling rcriod shall  be  tl1e  one  which  is the  first to expire.  The 
communication  of  this  information shall  be  considered  as  constituting  tt;e 
unreserved  and  irrevocable consent  of  the  applicant  to the deposited matter 
being  made  available  to  the  public  in  accordance  with  this  Article. 
3.a)  Unless  the  application  has  been  refused or 11ithdrawn  or  is deemed  to  be 
withdrawn,  the deposited matter  shall  be  available  upon  request: 
(i)  to  any  person  from  the date  of  publication of the  patent 
application,  and 
(ii)  to  any  person  having  a  right  to  inspect  the  files  under  the 
provisions  of  national  patent  law  relating to applications  under 
which  rights  are  invoked  against  such  a  party,  prior  to  the date  of 
publication; 
b)  Subject  to the provisions  of  paragraph  4,  such  availability shall  be 
effected by  the  issue  of  a  sample  of  the  deposited matter  to  the  person 
making  the  request  <hereinafter  referred  to  as  the  "requester'').  Said 
issue  shall  be  made  only if the  requester  has  undertaken  vis-a-vis  th2 
applicant  for  or  proprietor of  the  patent: 
(i)  not  to  make  the deposited matter  or  any  matter  derived  therefrom 
available  to  any  third party; 
Cii)  to use  the deposited matter or  any  matter derived  therefrom  in  any 
country  only  for  experimental  purposes  concerning  the  invention,  with 
the  proviso that  this  restriction will  cease,  in  the  country of  the 
p~tcnt right  on  the basis of  which  the  sample  of  the deposited matter 
was  obtained,  with  the  gra~t of  a  patent  or other  ~nforceable right 
in  the  invention  involved.  This  provision shall not  apply  in the 
country of  the patent.right on  the  basis  of  which  tf.e  sample  of  the 
deposited mattrr  was  obtained  insofar  as  the  requester  is using  the - 81  -
matter  under  a  compulsory  License.  The  term  "compulsory  License'' 
shall  be  construed  as  including~ officio  licenses  and  the  right  to 
use  patented  inventions  in  the  public  interest. 
4.  Until  the date  on  which  the technical  preparations  for  publication of  the 
application are deemed  to  have  been  completed,  the  applicant  may  inform  the 
national  patent office that,  until  the publication of  the  mention  of  the  grant 
of  the  patent,  the  availability referred  to  in  paragraph  3  shall  be  effected 
only  by  the  issue  of  a  sample  to  an  expert  nominated  by  the  requester. 
5.  The  follo~ing may  be  nominated  as  an  expert: 
(a)  any  natural  person  provided  that  the  requester  furnishes  evidence, 
when  filing the  request,  that  the  nomination  has  the  approval  of  the 
applicant; 
(b)  any  natural  person  recognised  as  an  expert  by  the national  patent 
office.  The  ~omination shall  be  accompanied  by  an  undertaking  from  the 
expert  vis-a-vis  the  applicant;  paragraphs  3(b)(i)  and  (ii)  shall 
apply,  the  requester  being  regarded as  a  third party. 
6.  For  the  purposes  of  paragraph 3(b),  any  matter derived  from  the  deposited 
matter  shall  be  deemed  to  be  any  matter  derived  therefrom  by  culturing or  in 
any  other  way  of  replication  which  matter still exhibits  those  characteristics 
of  the  deposited matter  which  are essential  to or  for  ~arrying out  the 
invention.  ThP  undertaking  referred to  in  paragraph  3(b)  shall  not  impede  a 
deposit  of  derived  matter,  necessary  for  the  purposes  of  patent  procedure. 
7.  The  request  provided  for  in paragraph  3  shall  be  submitted to  the national 
patent  office  on  a,  form  recognised by  that office.  The  national  patent  office 
shall certify on  the  form  that  a  national  patent  application  referring to the 
deposit  of  the  micro-organism  or other self-replicable matter  hds  been  filed, 
and  that  the  requester  or  the  expert  nominated  by  him  is entitled to  the  issue 
' 
of  a  sample  of the  micro-organism or other self-replicable matter. n-. 
UL 
~.  T~e national  patent  office shall  transmit  a  copy  of  the  request,  with  the 
certification provided  for  in paragraph  7  to  the depositary  institution as 
well  as  to  the  applicant  for,  or  the proprietor of,  the patent. 
9.  Member  States shall designate  recognised depositary  institutions  for 
purposes  of  this Article. 
10.  If  a  micro-organism or other self-replicable material  has  been  deposited 
in  accordance  with  paragraphs  1  and  2  and  has  become  available to  any  person 
or  an  expert  in  accordance  with  paragraph  3  or  4,  it shall  henceforth  be 
regarded available to the public  in accordance  with  paragraph  1. 
Article  16 
1.  If  a  micro-organism or other self-replicable mbtter  dep~sited in 
accordance  with  Article  15  ceases  to be  available  from  the  institution with 
which  it was  deposited because: 
(a)  the micro-organism or other self-replicable matter  is  no  longer 
viable·,  or 
(b)  for  any  other  reason  the depositary  institution is unable  to supply 
samples, 
and  if the  micro-organism or  othe~ self-replicable matter  has  not  been 
transferred to another depositary institution  recognised  for  the  purposes  of 
Article  15,  from  which  it continues to be  available,  an  interruption in 
availability shall  be  deemed  not  to have  occurred if a  new  deposit  of  the 
micro-organism or other self-replicable matter originally deposited  is made 
within  a  period of  three months  from  the date  on  ~hich the depositor  was 
notified of  the  interruption by  the  depositary  institution and  if a  copy  of 
the  receipt  of the deposit  issued by  the  i~stitution is  forwarded  to the 
national  patent  office within  four  months  from  the date of  the  new  deposit 
stating the  number  of  the  application or of  the  national  patent. - 83  -
2.  In the  case  provided  for  in  paragraph  1(a), the  new  deposit  shall  be  made 
with  the depositary  institution with  which  the original  deposit  was  made;  in 
the  cases  provided  for  in  paragraph  1(b),  it  may  be  made  with  another 
depositary  institution recognised for  the purposes  of  Article  15(9). 
3.  Where  the  institution with  which  the original  deposit  was  made  ceases  to 
be  recognised  for  the purposes of the application of  Article 15,  whether 
entirely or  for  the  kind  of  micro-organism or other self-replicable matter  to 
which  the .deposited micro-organism or other self-replicable matter  belongs,  or 
where  that  institution discontinues,  temporarily or definitively,  the 
performance  of  its functions  as  regards deposited micro-organisms  or  other 
self-replicable matter,  and  the notification  referred to  in  paragraph  1  from 
the depositary  institution is not  received within  six  months  from  the  date  of 
such  event,  the  three-month  period  referred  to  in paragraph  1  shall  begin  on 
the date on  whict:  this event  is announced  in  the official publication of  the 
national  patent office. 
4.  Any  new  deposit  shall  be  accompanied  by  a  statement  signed  by  the 
depositor  alleging  that  the  newly  deposited micro-organism or other 
self-replicable matter  is the  same  as  that  originally deposited. 
5.  If  the  new  deposit  provided  for  in the  present  Article  has  been  made  under 
the  Budapest  Treaty  on  the  International  Recognition  of  the  Deposit  of 
Micro-organis~s for  the Purposes  of  Patent  Procedure of  28  April  1977,  the 
provisions  of  that  Treaty  shall prevail  in  case  of  conflict. 
6.  If  a  deposit  is  not  accepted or if the deposited material  is no  Longer 
available  from  the  depository  institution and  a  re-deposit  according  to 
paragraphs  (1)  through  (5)  docs  not  or could not  remedy  the unavailability, 
such  undvailability shall not  affect the patentability of  the  invention if the 
applicant/patentee  provide~ the  requesting party entitled to  receive  a  sample 
with  such  sample  certifying its identity with  the material  used  in  the 
invention or obtained as  the  invention or  ~ith the originally deposited 
material,  as  the  case  may  be. - 84  -
7.  If a  patent  is deemed  invalid because  the patentee  can  no  longer  provide 
for  a  sample  of  the  deposited material  in  accordance  with  this article,  such 
invalidity shall  in  no  case  have  retroactive effects. 
CHAPTER  5 
Reversal  of the Burden  of Proof 
Article 17 
1.  If  the  subject  matter of  a  patent  is a  process  for obtaining  a  new  or 
known  product,  the  same  product  when  produced  by  any  other party shall,  in  the 
absence  of  proof  to the  contrary, be  deemed  to have  been  obtained  by  the 
patented process,  if a  necessary  means  to carry out  the  process  had  been 
deposited  in accordance  with  Article 14  and  had  been  released  to  a  third 
party. 
2.  In  the  adduction of  proof  to the contrary,  the  legitimate  interests  of  the 
defendant  in protecting his  manufacturing  and  business  secrets shall  be  taken 
into account. 
CHAPTER  6 
Miscellaneous 
Any  exclusion from  patentability or from  the field of  industrial applicability 
cif  surgical or  di~gnostic methods  practised on  an  animal body  shall apply  to 
such  methods  only if practised for' a  therapeutic  purpose. - 85  -
Article  19 
For  the  purposes  of this  Directive: 
(a)  the  word  "micro-organism",  where  used,  shall  be  interpreted  in its 
broadest  sense  as  including all microbiological  entities capable of 
replication, e.g.  as  comprising,  inter alia, bacteria,  fungi,  viruses, 
mycoplasmae,  rickettsiae,  algae,  protozoa,  and  cells;  and 
(b)  the  words  "self-replicable matter",  where  used,  shall  be  interpreted to 
comprise  also matter possessing  the genetic material  necessary to direct 
its own  replication via  a  host  organism  or  in any  other  indirect  way,  e.g. 
as  comprising,  inter alia,  seeds,  plasmids,  DNA  sequences,  protoplasts, 
replicons  and  tissue  cultures. 
Article  20 
1.  Member  States shall  bring  into force  the  Laws  necessary  to  comply  with 
this  Directive  not  Later  than  31  December  1990. 
2.  Member  States shall  communicate  to the  Commission  the texts of the main 
provisions of national  Law  which  they  adopt  in the  field  covered  by  this 
Directive. 
Article  21 
This  Directive  is addressed to the  Member  States. 
Done  at  Brussels,  • • .  • ... • • • • •  198 .• 
For  the  Council 
The  ~resident 